

# Using generalized additive models to analyze biomedical non-linear longitudinal data

*Beyond repeated measures ANOVA and Linear Mixed Models*

Ariel I. Mundo<sup>1</sup>, John R. Tipton<sup>2</sup>, and Timothy J. Muldoon<sup>1</sup>

<sup>1</sup>Department of Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA

<sup>2</sup>Department of Mathematical Sciences, University of Arkansas, Fayetteville, AR, USA

## Contents

<b>1</b>	<b>Abstract</b>	<b>2</b>
<b>2</b>	<b>Background</b>	<b>2</b>
<b>3</b>	<b>Challenges presented by longitudinal studies</b>	<b>4</b>
3.1	The repeated measures ANOVA . . . . .	5
3.2	Linear relationship . . . . .	5
3.3	Covariance in rm-ANOVA and LMEMs . . . . .	6
3.4	Missing observations . . . . .	6
3.5	What do an rm-ANOVA and LMEM fit look like? A visual representation using simulated data	7
<b>4</b>	<b>GAMs as a special case of Generalized Linear Models</b>	<b>9</b>
4.1	GAMs and Basis Functions . . . . .	9
<b>5</b>	<b>The analysis of longitudinal biomedical data using GAMs</b>	<b>12</b>
5.1	Simulated data . . . . .	12
5.2	An interaction GAM for longitudinal data . . . . .	12
5.3	Determination of significance in GAMs for longitudinal data . . . . .	14
<b>6</b>	<b>Discussion</b>	<b>15</b>
<b>7</b>	<b>Conclusion</b>	<b>16</b>
<b>8</b>	<b>Acknowledgements</b>	<b>16</b>
<b>9</b>	<b>References</b>	<b>17</b>

26	<b>A Code for Manuscript data</b>	<b>20</b>
27	A.1 Compound symmetry and independent errors in linear and quadratic responses . . . . .	21
28	A.2 Basis functions and GAMs . . . . .	27
29	<b>B Longitudinal biomedical data simulation and GAMs</b>	<b>31</b>
30	B.1 A basic Workflow for GAMs . . . . .	33
31	<b>C GAM and Linear model plots and Missing data</b>	<b>44</b>
32	C.1 GAM and Linear model plots . . . . .	44
33	C.2 Working with Missing data in GAMs . . . . .	46
34	C.3 Pairwise comparisons in GAMs: full and missing data cases . . . . .	48

## 35 1 Abstract

36 In biomedical research, the outcome of longitudinal studies has been traditionally analyzed using the *re-*  
37 *peated measures analysis of variance* (rm-ANOVA) or more recently, *linear mixed models* (LMEMs). Al-  
38 though LMEMs are less restrictive than rm-ANOVA in terms of correlation and missing observations, both  
39 methodologies share an assumption of linearity in the measured response, which results in biased estimates  
40 and unreliable inference when they are used to analyze data where the trends are non-linear. In contrast,  
41 generalized additive models (GAMs) relax the linearity assumption, and allow the data to determine the fit  
42 of the model while permitting missing observations and different correlation structures. Therefore, GAMs  
43 present an excellent choice to analyze non-linear longitudinal data in the context of biomedical research.  
44 This paper summarizes the limitations of rm-ANOVA and LMEMs and uses simulated data to visually  
45 show how both methods produce biased estimates when used on non-linear data. We also present the ba-  
46 sic theory of GAMs, and use simulated data that follows trends reported in the biomedical literature to  
47 demonstrate how these models are implemented in R via the package *mgcv*, showing that GAMs are able  
48 to produce estimates that are consistent with the trends of non-linear data even if the case when missing  
49 observations exist. To make this work reproducible, the code and data used in this paper are available at:  
50 <https://github.com/aimundo/GAMs-biomedical-research>.

## 51 2 Background

52 Longitudinal studies are designed to repeatedly measure a variable of interest in a group (or groups) of  
53 subjects, with the intention of observing the evolution of effect across time rather than analyzing a single  
54 time point (e.g., a cross-sectional study). Biomedical research frequently uses longitudinal studies to analyze  
55 the evolution of a “treatment” effect across multiple time points; and in such studies the subjects of analysis  
56 range from animals (mice, rats, rabbits), to human patients, cells, or blood samples, among many others.  
57 Tumor response [1–4], antibody expression [5,6], and cell metabolism [7,8] are examples of the different  
58 situations where researchers have used longitudinal designs to study some physiological response. Because  
59 the frequency of the measurements in a longitudinal study is dependent on the biological phenomena of  
60 interest and the experimental design of the study, the frequency of such measurements can range from minute  
61 intervals to study a short-term response such as anesthesia effects in animals[9], to weekly measurements  
62 to analyze a mid-term response like the evolution of dermatitis symptoms in breast cancer patients [10], to  
63 monthly measurements to study a long-term response such as mouth opening following radiotherapy (RT)  
64 in neck cancer patients [11].

65 Traditionally, a “frequentist” or “classical” statistical paradigm is used in biomedical research to derive  
66 inferences from a longitudinal study. The frequentist paradigm regards probability as the limit of the

expected outcome when an experiment is repeated a large number of times [12], and such view is applied to the analysis of longitudinal data by assuming a null hypothesis under a statistical model that is often an *analysis of variance over repeated measures* (repeated measures ANOVA or rm-ANOVA). The rm-ANOVA model makes three key assumptions regarding longitudinal data: 1) linearity of the response across time, 2) constant correlation across same-subject measurements, and 3) observations from each subject are obtained at all time points through the study (a condition also known as *complete observations*) [13,14].

The expected linear behavior of the response through time is a key requisite in rm-ANOVA [15]. This “linearity assumption” in rm-ANOVA implies that the model is misspecified when the data does not follow a linear trend, which results in unreliable inference. In biomedical research, non-linear trends are the norm rather than the exception in longitudinal studies. A particular example of this non-linear behavior in longitudinal data arises in measurements of tumor response to chemo and/or radiotherapy in preclinical and clinical settings [1,8,16]. These studies have shown that the collected signal does not follow a linear trend over time, and presents extreme variability at different time points, making the fit of rm-ANOVA model inconsistent with the observed variation. Therefore, when rm-ANOVA is used to draw inference of such data the estimates are inevitably biased, because the model is only able to accommodate linear trends that fail to adequately represent the biological phenomenon of interest.

A *post hoc* analysis is often used in conjunction with rm-ANOVA to perform repeated comparisons to estimate a *p-value*, which in turn is used as a measure of significance. Although it is possible that a *post hoc* analysis of rm-ANOVA is able to find “significant” *p-values* ( $p < 0.05$ ) from non-linear data, the validity of such metric is dependent on how adequate the model fits the data. In other words, *p-values* are valid only if the model and the data have good agreement; if that is not the case, a “Type III” error (known as “model misspecification”) occurs [17]. For example, model misspecification will occur when a model that is only able to explain linear responses (such as rm-ANOVA) is fitted to data that follows a quadratic trend, thereby causing the resulting *p-values* and parameter estimates to be invalid [18].

Additionally, the *p-value* itself is highly variable, and multiple comparisons can inflate the false positivity rate (Type I error or  $\alpha$ ) [19,20], consequently biasing the conclusions of the study. Corrections exist to address the Type I error issue of multiple comparisons (such as Bonferroni [21]), but they in turn reduce statistical power ( $1 - \beta$ ) [22], and lead to increased Type II error (failing to reject the null hypothesis when the null hypothesis is false) [23,24]. Therefore, the tradeoff of *post hoc* comparisons in rm-ANOVA between Type I, II and III errors might be difficult to resolve in a biomedical longitudinal study where a delicate balance exists between statistical power and sample size.

On the other hand, the assumption of constant correlation in rm-ANOVA (often known as the *compound symmetry assumption*) is typically unreasonable because correlation between the measured responses often diminishes as the time interval between the observation increases [25]. Corrections can be made in rm-ANOVA in the absence of compound symmetry [26,27], but the effectiveness of the correction is limited by the size of the sample, the number of measurements [28], and group sizes [29]. In the case of biomedical research, where living subjects are frequently used, sample sizes are often not “large” due to ethical and budgetary reasons [30] which might cause the corrections for lack of compound symmetry to be ineffective.

Due to a variety of causes, the number of observations during a study can vary between all subjects. For example, in a clinical trial patients may voluntarily withdraw, whereas attrition due to injury or weight loss in preclinical animal studies is possible. It is even plausible that unexpected complications with equipment or supplies arise that prevent the researcher from collecting measurements at certain time points. In each of these missing data scenarios, the *complete observations* assumption of classical rm-ANOVA is violated. When incomplete observations occur, a rm-ANOVA model is fit by excluding all subjects with missing observations from the analysis [13]. This elimination of partially missing data from the analysis can result in increased costs if the desired statistical power is not met with the remaining observations, because it would be necessary to enroll more subjects. At the same time, if the excluded observations contain insightful information that is not used, their elimination from the analysis may limit the demonstration of significant differences between groups.

During the last decade, the biomedical community has started to recognize the limitations of rm-ANOVA in the analysis of longitudinal data. The recognition on the shortcomings of rm-ANOVA is exemplified by the

use of linear mixed effects models (LMEMs) by certain groups to analyze longitudinal tumor response data [8,16]. Briefly, LMEMs incorporate *fixed effects*, which correspond to the levels of experimental factors in the study (e.g., the different drug regimens in a clinical trial), and *random effects*, which account for random variation within the population (e.g., the individual-level differences not due to treatment such as weight or age). When compared to the traditional rm-ANOVA, LMEMs are more flexible as they can accommodate missing observations for multiple subjects and allow different modeling strategies for the variability within each measure in every subject [15]. However, LMEMs impose restrictions in the distribution of the errors of the random effects, which need to be normally distributed and independent [13,31]. And even more importantly, LMEMs also assume a linear relationship between the response and time [15], making them unsuitable to analyze non-linear data.

As the rm-ANOVA and the more flexible LMEM approaches make overly restrictive assumptions regarding the linearity of the response, there is a need for biomedical researchers to explore the use of additional statistical tools that allow the data (and not an assumption in trend) to determine the trend of the fitted model, to enable appropriate inference.

In this regard, generalized additive models (GAMs) present an alternative approach to analyze longitudinal data. Although not frequently used by the biomedical community, these semi-parametric models are customarily used in other fields to analyze longitudinal data. Examples of the use of GAMs include the analysis of temporal variations in geochemical and palaeoecological data [32–34], health-environment interactions [35] and the dynamics of government in political science [36]. There are several advantages of GAMs over LMEMs and rm-ANOVA models: 1) GAMs can fit a more flexible class of smooth responses that enable the data to dictate the trend in the fit of the model, 2) they can model non-constant correlation between repeated measurements [37] and 3) can easily accommodate missing observations. Therefore, GAMs can provide a more flexible statistical approach to analyze non-linear biomedical longitudinal data than LMEMs and rm-ANOVA.

The current advances in programming languages designed for statistical analysis (specifically R), have eased the computational implementation of traditional models such as rm-ANOVA and more complex approaches such as LMEMs and GAMs. In particular, R[38] has an extensive collection of documentation and functions to fit GAMs in the package *mgcv* [37,39] that not only speed up the initial stages of the analysis but also enable the use of advanced modeling structures (e.g. hierarchical models, confidence interval comparisons) without requiring advanced programming skills from the user. At the same time, R has many tools that simplify data simulation, an emerging strategy used to test statistical models [28]. Data simulation methods allow the researcher to create and explore different alternatives for analysis without collecting information in the field, reducing the time window between experiment design and its implementation, and simulation can be also used for power calculations and study design questions.

This work provides biomedical researchers with a clear understanding of the theory and the practice of using GAMs to analyze longitudinal data using by focusing on four areas. First, the limitations of LMEMs and rm-ANOVA regarding linearity of response, constant correlation structures and missing observations is explained in detail. Second, the key theoretical elements of GAMs are presented using clear and simple mathematical notation while explaining the context and interpretation of the equations. Third, using simulated data that reproduces patterns in previously reported studies [16] we illustrate the type of non-linear longitudinal data that often occurs in biomedical research. The simulated data experiments highlight the differences in inference between rm-ANOVA, LMEMs and GAMs on data similar to what is commonly observed in biomedical studies. Finally, reproducibility is emphasized by providing the code to generate the simulated data and the implementation of different models in R, in conjunction with a step-by-step guide demonstrating how to fit models of increasing complexity.

In summary, this work will allow biomedical researchers to identify when the use of GAMs instead of rm-ANOVA or LMEMs is appropriate to analyze longitudinal data, and provide guidance on the implementation of these models by improving the standards for reproducibility in biomedical research.

### 3 Challenges presented by longitudinal studies

### 3.1 The repeated measures ANOVA

The *repeated measures analysis of variance* (rm-ANOVA) is the standard statistical analysis for longitudinal data in biomedical research. This statistical methodology requires certain assumptions for the model to be valid. From a practical view, the assumptions can be divided in three areas: 1) linear relationship between covariates and response, 2) a constant correlation between measurements, and, 3) complete observations for all subjects. Each one of these assumptions is discussed below.

### 3.2 Linear relationship

#### 3.2.1 The repeated measures ANOVA case

In a longitudinal biomedical study, two or more groups of subjects (e.g., human subject, mice, samples) are subject to different treatments (e.g., a “treatment” group receives a novel drug or intervention vs. a “control” group that receives a placebo), and measurements from each subject within each group are collected at specific time points. The collected response is modeled with *fixed* components. The *fixed* component can be understood as a constant value in the response which the researcher is interested in measuring, i.e., the average effect of the novel drug/intervention in the “treatment” group.

Mathematically speaking, a rm-ANOVA model with an interaction can be written as:

$$y_{ijt} = \beta_0 + \beta_1 \times time_t + \beta_2 \times treatment_j + \beta_3 \times time_t \times treatment_j + \varepsilon_{ijt} \quad (1)$$

In this model  $y_{ijt}$  is the response for subject  $i$ , in treatment group  $j$  at time  $t$ , which can be decomposed in a mean value  $\beta_0$ , *fixed effects* of time ( $time_t$ ), treatment ( $treatment_j$ ) and their interaction  $time_t * treatment_j$  which have linear slopes given by  $\beta_1, \beta_2$  and  $\beta_3$ , respectively. Independent errors  $\varepsilon_{tij}$  represent random variation not explained by the *fixed* effects, and are assumed to be  $\sim N(0, \sigma^2)$  (independently and identically normally distributed with mean zero and variance  $\sigma^2$ ). In a biomedical research context, suppose two treatments groups are used in a study (e.g., “placebo” vs. “novel drug” or “saline” vs. “chemotherapy”). Then, the group terms in Equation (1) can be written as below with  $treatment_j = 0$  representing the first treatment group (Group A) and  $treatment_j = 1$  representing the second treatment group (Group B). The linear models then can be expressed as

$$y_{ijt} = \begin{cases} \beta_0 + \beta_1 \times time_t + \varepsilon_{ijt} & \text{if Group A} \\ \beta_0 + \beta_2 + \beta_1 \times time_t + \beta_3 \times time_t + \varepsilon_{ijt} & \text{if Group B} \end{cases} \quad (2)$$

To further simplify the expression, substitute  $\widetilde{\beta}_0 = \beta_0 + \beta_2$  and  $\widetilde{\beta}_1 = \beta_1 + \beta_3$  in the equation for Group B. This substitution allows for a different intercept and slope for Groups A and B. The model is then written as

$$y_{ijt} = \begin{cases} \beta_0 + \beta_1 \times time_t + \varepsilon_{ijt} & \text{if Group A} \\ \widetilde{\beta}_0 + \widetilde{\beta}_1 \times time_t + \varepsilon_{ijt} & \text{if Group B} \end{cases} \quad (3)$$

Presenting the model in this manner makes clear that when treating different groups, an rm-ANOVA model is able to accommodate non-parallel lines in each case (different intercepts and slopes per group). In other words, the rm-ANOVA model “expects” a linear relationship between the covariates and the response, this means that either presented as Equation (1), Equation (2) or Equation (3), an rm-ANOVA model is only able to accommodate linear patterns in the data. If the data show non-linear behavior, the rm-ANOVA model will approximate this behavior with non-parallel lines.

### 3.2.2 The Linear Mixed Model Case

A linear mixed model (LMEM) is a class of statistical model that incorporates *fixed effects* to model the relationship between the covariates and the response, and *random effects* to model subject variability that is not the primary focus of the study but that might be important to distinguish [15,40]. A LMEM with interaction between time and treatment for a longitudinal study can be written as:

$$y_{ijt} = \beta_0 + \beta_1 \times time_t + \beta_2 \times treatment_j + \beta_3 \times time_t \times treatment_j + \mu_{ij} + \varepsilon_{ijt} \quad (4)$$

When Equation (1) and Equation (4) are compared, it is easily noticeable that LMEM and rm-ANOVA have the same construction regarding the *fixed effects* of time and treatment, but that the LMEM incorporates an additional source of variation (the term  $\mu_{ij}$ ). This term  $\mu_{ij}$  is the one that corresponds to the *random effect*, accounting for variability in each subject within each group. The *random* component can also be understood as used to model some “noise” in the response, but that is intended to be analyzed and disentangled from the “global noise” term  $\varepsilon_{ijt}$  from Equation (1).

For example, if the blood concentration of the drug is measured in certain subjects in the early hours of the morning while other subjects are measured in the afternoon, it is possible that the difference in the collection time introduces some “noise” in the data. As the name suggests, this “random” variability needs to be modeled as a variable rather than as a constant value. The *random effect*  $\mu_{ij}$  in Equation (4) is assumed to be  $\mu_{ij} \sim N(0, \sigma_\mu^2)$ . In essence, the *random effect* in a LMEM enables to fit models with different slopes at the subject-level [15]. However, the expected linear relationship of the covariates and the response in Equation (1) and in Equation (4) is essentially the same, representing a major limitation of LMEMs to fit a non-linear response.

### 3.3 Covariance in rm-ANOVA and LMEMs

In a longitudinal study there is an expected *covariance* between repeated measurements on the same subject, and because repeated measures occur in the subjects within each group, there is a *covariance* between measurements at each time point within each group. The *covariance matrix* (also known as the variance-covariance matrix) is a matrix that captures the variation between and within subjects in a longitudinal study [41] (For an in-depth analysis of the covariance matrix see [40,42]).

In the case of an rm-ANOVA analysis, it is typically assumed that the covariance matrix has a specific construction known as *compound symmetry* (also known as “sphericity” or “circularity”). Under this assumption, the between-subject variance and within-subject correlation are constant across time [26,42,43]. However, it has been shown that this condition is frequently not justified because the correlation between measurements tends to change over time [44]; and it is higher between consecutive measurements [13,25]. Although corrections can be made (such as Huynh-Feldt or Greenhouse-Geisser) [26,27] the effectiveness of each correction is limited because it depends on the size of the sample, the number of repeated measurements [28], and they are not robust if the group sizes are unbalanced [29]. Because biomedical longitudinal studies are often limited in sample size and can have an imbalanced design, the corrections required to use an rm-ANOVA model may not be able to provide a reasonable adjustment that makes the model valid.

In the case of LMEMs, one key advantage over rm-ANOVA is that they allow different structures for the variance-covariance matrix including exponential, autoregressive of order 1, rational quadratic and others [15]. Nevertheless, the analysis required to determine an appropriate variance-covariance structure for the data can be a challenging process by itself. Overall, the spherical assumption for rm-ANOVA may not capture the natural variations of the correlation in the data, and can bias the inferences from the analysis.

### 3.4 Missing observations

Missing observations are an issue that arises frequently in longitudinal studies. In biomedical research, this situation can be caused by reasons beyond the control of the investigator [45]. Dropout from patients

and attrition or injury in animals are among the reasons for missing observations. Statistically, missing information can be classified as *missing at random* (MAR), *missing completely at random* (MCAR), and *missing not at random* (MNAR) [42]. In a MAR scenario, the pattern of the missing information is related to some variable in the data, but it is not related to the variable of interest [46]. If the data are MCAR, this means that the missingness is completely unrelated to the collected information [47], and in the case of MNAR the missing values are dependent on their value.

An rm-ANOVA model assumes complete observations for all subjects, and therefore subjects with one or more missing observations are excluded from the analysis. This is inconvenient because the remaining subjects might not accurately represent the population, and statistical power is affected by this reduction in sample size [48]. In the case of LMEMs, inferences from the model are valid when missing observations in the data exist that are MAR or MCAR [40]. For example, if attrition occurs in all mice that had lower weights at the beginning of a chemotherapy response study, the missing data can be considered MAR because the missingness is unrelated to other variables of interest.

### 3.5 What do an rm-ANOVA and LMEM fit look like? A visual representation using simulated data

To visually demonstrate the limitations of rm-ANOVA and LMEMs for non-linear longitudinal data, this section presents a simulation experiment of a normally distributed response of two groups of 10 subjects each. An rm-ANOVA model (Equation (1)), and a LMEM (Equation (4)) are fitted to each group, using R[38] and the package *nlme*[49].

Briefly, two cases for the mean responses for each group are considered: in the first case, the mean response in each group is a linear function over time with different intercepts and slopes; a negative slope is used for Group 1 and a positive slope is used for Group 2 (Figure 1, A). In the second case, a second-degree polynomial (quadratic) function is used for the mean response per group: the quadratic function is concave down for Group 1 and it is concave up for Group 2 (Figure 1, C). In both the linear and quadratic simulated data, the groups start with the same mean value at the first time point. This is intentional in order to simulate the expected temporal evolution of some physiological quantity, which is typical in biomedical experiments.

Specifically, the rationale for the chosen linear and quadratic functions is the expectation that a measured response in two treatment groups is similar in the initial phase of the study, but as therapy progresses a divergence in the trend of the response indicates a treatment effect. In other words, Group 1 can be thought as a “Control” group and Group 2 as a “Treatment” group. From the mean response per group (linear or quadratic), the variability or “error” of individual responses within each group is simulated using a covariance matrix with compound symmetry (constant variance across time). Thus, the response per subject in both the linear and quadratic simulation corresponds to the mean response per group plus the error (Figure 1 B,D).

A more comprehensive exploration of the fit of rm-ANOVA and LMEMs for linear and non-linear longitudinal appears in Figure 5 and Figure 6 in the Appendix, where simulation with compound symmetry and independent errors (errors generated from a normal distribution that are not constant over time) and the plot of simulated errors, and fitted parameters is presented. We are aware that the simulated data used in this section present an extreme case that might not occur frequently in biomedical research, but they are used as a representation of the consequences of modeling non-linear data with a linear model such as rm-ANOVA or LMEMs. Of notice, Section 5 uses simulated data that does follow reported trends in the biomedical literature.




Figure 1: Simulated linear responses from two groups with correlated (top row) or independent (bottom row) errors using a LMEM and a rm-ANOVA model. A, D: Simulated data with known mean response (linear or quadratic, thin lines) and individual responses (points) showing the dispersion of the data. B,E: Estimates from the rm-ANOVA model for the mean group response (linear or quadratic). Points represent the original raw data. The rm-ANOVA model not only fails to pick the trend of the quadratic data but also assigns a global estimate that does not take between-subject variation. C, F: Estimates from the LMEM model in the linear and quadratic case. The LMEM incorporates a random effect for each subject, but this model and the rm-ANOVA model are unable to follow the trend of the data in each group and grossly bias the initial estimates for each group.

The simulation shows that the fit produced by the LMEM and the rm-ANOVA model is good for linear data, as the predictions for the mean response are reasonably close to the “truth” of the simulated data (Figure 1, B, E). When the linearity and compound symmetry assumptions are met, the model approximates well the individual trends and the mean trends by group.

However, consider the case when the data follows a non-linear trend, such as the simulated data in Figure 1, C. Here, the mean response per group was simulated using a quadratic function but errors, individual responses and the rm-ANOVA model were produced in the same manner as in (Figure 1 A and B). The mean response in the simulated data with quadratic behavior is changing in each group through the timeline, and the mean value is the same as the initial value by the fifth time point for each group. Fitting an rm-ANOVA model (1) or a LMEM (4) to this data produces the fit that appears in panels E and F in Figure 1.

A comparison of the fitted mean response of the LMEM and the rm-ANOVA model to the simulated data in Figure ((1, E, F) indicates that the models are not capturing the changes within each group. Specifically, note that the fitted mean response of both models (panel E, F) show that the change (increase for Treatment 1 or decrease for Treatment 2) in the response through time points 2 and 4 is not being captured. The LMEM



is only able to account for between-subject variation by providing different intercepts to each subject, but both models are not able to capture the fact that the initial values are the same in each group, and instead fit non-parallel lines that have initial values that are markedly different from the “true” initial values in each case (compare panel D with panels E and F). If such a change has important physiological implications, both rm-ANOVA and LMEMs omit it from the fitted mean response. Thus, even though the model correctly detects a divergence between treatment groups, the exact nature of this difference is not correctly identified, limiting valuable inferences from the data.

This section has used simulation to better convey the limitations of linearity and correlation in the response in non-linear data. Although the model fitted to the simulated data was an rm-ANOVA model, the main issue of an expected linear trend in the response is the same in the case of a LMEM. In the following section, we present generalized additive models (GAMs) as a data-driven alternative method to analyze longitudinal non-linear data.

## 4 GAMs as a special case of Generalized Linear Models

### 4.1 GAMs and Basis Functions

Generalized linear models (GLMs) are a family of models that fit a linear response function to data that do not have normally distributed errors[50]. In contrast, GAMs are a family of regression-based methods for estimating smoothly varying trends and are a broader class of models that contain the GLM family as a special case[34,37,51]. A GAM model can be written as:

$$y_{ijt} = \beta_0 + f(x_t | \beta_j) + \varepsilon_{ijt} \quad (5)$$

Where  $y_{ijt}$  is the response at time  $t$  of subject  $i$  in group  $j$ ,  $\beta_0$  is the expected value at time 0, the change of  $y_{ijt}$  over time is represented by the *smooth function*  $f(x_t | \beta_j)$  with inputs as the covariates  $x_t$  and parameters  $\beta_j$ , and  $\varepsilon_{ijt}$  represents the residual error.

In contrast to the linear functions used to model the relationship between the covariates and the response in rm-ANOVA or LMEM, GAMs use more flexible *smooth functions*. This approach is advantageous as it does not restrict the model to a linear relationship, although a GAM will estimate a linear relationship if the data is consistent with a linear response. One possible set of functions for  $f(x_t | \beta_j)$  that allow for non-linear responses are polynomials, but a major limitation is that polynomials create a “global” fit as they assume that the same relationship exists everywhere, which can cause problems with inference [36]. In particular, polynomial fits are known to show boundary effects because as  $t$  goes to  $\pm\infty$ ,  $f(x_t | \beta_j)$  goes to  $\pm\infty$  which is almost always unrealistic and causes bias at the endpoints of the time period.

The smooth functional relationship between the covariates and the response in GAMs is specified using a semi-parametric relationship that can be fit within the GLM framework, by using *basis function* expansions of the covariates and by estimating random coefficients associated with these basis functions. A *basis* is a set of functions that spans the mathematical space where the smooths that approximate  $f(x_t | \beta_j)$  exist [34]. For the linear model in Equation (1), the basis coefficients are  $\beta_1$ ,  $\beta_2$  and  $\beta_3$  and the basis vectors are  $time_t$ ,  $treatment_j$  and  $time_t \times treatment_j$ . The basis function then, is the combination of basis coefficients and basis vectors that map the possible relationship between the covariates and the response [52], which in the case of Equation (1) is restricted to a linear family of functions. In the case of Equation (5), the basis functions are  $f(x_t | \beta_j)$ , which means that the model allows for non-linear relationships among the covariates.

Splines (cubic, thin plate, etc.) are commonly used *basis functions*; a cubic spline is a smooth curve constructed from cubic polynomials joined together in a manner that enforces smoothness, and thin plate regression splines are an optimized version that work well with noisy data [34,37]. Splines have a long history in solving semi-parametric statistical problems and are often a default choice to fit GAMs as they are

a simple, flexible and powerful option to obtain smoothness [53]. Therefore, this data-driven flexibility in GAMs overcomes the limitation that occurs in LMEMs and rm-ANOVA when the data is non linear.

To further clarify the concept of basis functions and smooth functions, consider the simulated response for Group 1 in Figure (1, C). The simplest GAM model that can be used to estimate such response is that of a single smooth term for the time effect; i.e., a model that fits a smooth to the trend of the group through time. The timeline can be divided in equally spaced *knots*, each knot being a region where a different basis function will be used. Because there are six timepoints for this group, five knots can be used. The model with five knots to construct the smooth term means that it will have four basis functions (plus one that corresponds to the intercept). The choice of basis functions is set using default values in the package *mgcv* depending on the number of knots. In Panel A of Figure 2, the four basis functions (and the intercept) are shown. Each of the basis functions is composed of six different points (because there are six points on the timeline). To control the “wiggleness” of the fit, each of the basis functions of Panel A is weighted by multiplying it by a coefficient according to the matrix of Panel B. The parameter estimates are penalized where the penalty reduces the “wiggleness” of the smooth fit to prevent overfitting: A weak penalty estimate will result in wiggly functions whereas a strong penalty estimate provides evidence that a linear response is appropriate.

In other words, the six points of each basis are multiplied by the corresponding coefficient in panel B, thereby increasing or decreasing the original basis functions of Panel A. In Figure 2, Panel C shows the resulting weighted basis functions. Note that the magnitude of the weighting for basis function 1 has resulted in a decrease of its overall value (because the coefficient for that basis function is less than 1). On the other hand, basis function 3 has roughly doubled its value. Finally, the weighted basis functions are added at each timepoint to produce the smooth term. The resulting smooth term for the effect of *time* is shown in Panel D (orange line) along the simulated values per group, which appear as points.




Figure 2: Basis functions for a single smoother for time with five knots. A: Basis functions for a single smoother for time for the simulated data of Group 1 from Figure 2, the intercept basis is not shown. B: Matrix for basis function weights. Each basis function is multiplied by a coefficient which can be positive or negative. The coefficient determines the overall effect of each basis in the final smoother. C: Weighted basis functions. Each of the four basis functions of panel A has been weighted by the corresponding coefficient shown in Panel B, note the corresponding increase (or decrease) of each basis. D: Smoother for time and original data points. The smoother (line) is the result of the sum of each penalized basis function at each time point, with simulated values for the group shown as points.

## 5 The analysis of longitudinal biomedical data using GAMs

The previous sections provided the basic framework to understand the GAM framework and how these models are more advantageous to analyze non-linear longitudinal data when compared to rm-ANOVA or LMEMs. This section will use simulation to present the practical implementation of GAMs for longitudinal biomedical data using R and the package `mgcv`. The code for the simulated data and figures, and a brief guide for model selection and diagnostics appear in the Appendix.

### 5.1 Simulated data

The simulated data is based on the reported longitudinal changes in oxygen saturation ( $\text{StO}_2$ ) in subcutaneous tumors that appear in Figure 3, C in [16]. In the paper, diffuse reflectance spectroscopy was used to quantify  $\text{StO}_2$  changes in both groups at the same time points (days 0, 2, 5, 7 and 10). In the “Treatment” group (chemotherapy) an increase in  $\text{StO}_2$  is observed through time, while a decrease is seen in the “Control” (saline) group. Following the reported trend, we simulated 10 normally distributed observations at each time point with a standard deviation (SD) of 10% (matching the SD in the original paper). The simulated and real data appear in Figure 3, A and the inset, respectively.

### 5.2 An interaction GAM for longitudinal data

An interaction effect is typically the main interest in longitudinal biomedical data, as it takes into account treatment, time, and their combination. In a practical sense, when a GAM is implemented for longitudinal data, a smooth can be added to the model for the *time* effect to account for the repeated measures over time. Although specific methods of how GAMs model correlation structures is a topic beyond the scope of this paper, it suffices to say that GAMs are flexible and can handle correlation structures beyond compound symmetry. A detailed description on basis functions and correlations can be found in [52].

For the data in Figure 3, A the main effect of interest is how  $\text{StO}_2$  changes over time for each treatment. To estimate this, the model incorporates independent smooths for *Group* and *Day*, respectively. The main thing to consider is that model syntax accounts for the fact that one of the variables is numeric (*Day*) and the other is a factor (*Group*). Because the smooths are centered at 0, the factor variable needs to be specified as a parametric term in order to identify any differences between the groups. Using R and the package `mgcv` the model syntax is:

```
m1 <- gam(StO2_sim ~ Group + s(Day, by=Group, k=5), method='REML', data=dat_sim)
```

This syntax specifies that `m1` will store the model, and that the change in the simulated oxygen saturation (`StO2_sim`) is modeled using independent smooths for `Group` and `Day` (the parenthesis preceded by `s`) using 5 knots. The smooth is constructed by default using thin plate regression splines, but other splines can be used if desired, including Gaussian process smooths [34]. The parametric term `Group` is added to quantify differences in the effect of treatment between groups, and the `method` chosen to estimate the smoothing parameters is the restricted maximum likelihood (REML) [37]. When the smooths are plotted over the raw data, it is clear that the model has been able to capture the trend of the change of  $\text{StO}_2$  for each group across time (Figure 3,B). Model diagnostics can be obtained using the `gam.check` function, and the function `appraise` from the package *gratia* [54]. A guide for model selection and diagnostics is in the Appendix, and an in-depth analysis can be found in [37] and [55].

One question that might arise at this point is “what is the fit that an rm-ANOVA model produces for the simulated data?” The rm-ANOVA model, which corresponds to Equation (1) is presented in Figure 3, C. This is a typical case of model misspecification: The slopes of each group are different, which would lead to a *p-value* indicating significance for the treatment and time effects, but the model is not capturing the changes that occur at days 2 and between days 5 and 7, whereas the GAM model is able to do so (Figure 3, B) .

409 Because GAMs do not require equally-spaced or complete observations for all subjects, they are advantageous  
 410 to analyze longitudinal data where missingness exists. The rationale behind this is that GAMs are able to  
 411 pick the trend in the data even when some observations are missing. However, this usually causes the  
 412 resulting smooths to have wider confidence intervals and less ability to pick certain trends. Consider the  
 413 simulated  $\text{StO}_2$  values from Figure (3, B). If 40% of the total observations are randomly deleted and the  
 414 same interaction GAM fitted for the complete dataset is used, the resulting smooths are still able to show a  
 415 different trend for each group, but it can be seen that the smooths overlap during the first 3 days because  
 416 with less data points, the trend is less pronounced than in the full dataset (3, D). Although the confidence  
 417 intervals have increased for both smooths, the model still shows different trends with as little as 4 observations  
 418 per group at certain time points.




Figure 3: Simulated data and smooths for oxygen saturation in tumors. A: Simulated data that follows previously reported trends (inset) in tumors under chemotherapy (Treatment) or saline (Control) treatment. Simulated data is from a normal distribution with standard deviation of 10% with 10 observations per time point. Lines indicate mean oxygen saturation B: Smooths from the GAM model for the full simulated data with interaction of Group and Treatment. Lines represent trends for each group, shaded regions are 95% confidence intervals. C: rm-ANOVA model for the simulated data, the model does not capture the changes in each group over time. D: Smooths for the GAM model for the simulated data with 40% of its observations missing. Lines represent trends for each group, shaded regions are 95% confidence intervals.




Figure 4: Pairwise comparisons for smooth terms. A: Pairwise comparisons for the full dataset. B: Pairwise comparisons for the dataset with missing observations. Significant differences exist where the interval does not cover 0. In both cases the effect of treatment is significant after day 3.

### 5.3 Determination of significance in GAMs for longitudinal data

At the core of a biomedical longitudinal study lies the question of a significant difference between the effect of two or more treatments in different groups. Whereas in *rm*-ANOVA a *post-hoc* analysis is required to answer such question by calculating some *p-values* after multiple comparisons, GAMs can use a different approach to estimate significance. In essence, the idea behind the estimation of significance in GAMs across different treatment groups is that if the *difference* between the empirical Bayesian confidence intervals of the fitted smooths for such groups is non-zero, then a significant difference exists at that time point(s). The absence of a *p-value* in this case might seem odd, but the empirical Bayesian confidence interval interpretation can be conceptualized in the following manner: Different trends in each group are an indication of an effect by the treatment. This is what happens for the simulated data in Figure 3, A where the chemotherapy causes  $\text{StO}_2$  to increase over time.

With this expectation of different trends in each group, computing the difference between the trends will identify if the observed change is significant. The difference between groups with similar trends is likely to yield zero, which would indicate that the treatment is not causing a change in the response in one of the groups (assuming the other group is a Control or Reference group).

Consider the calculation of pairwise differences for the smooths in Figure 3, B and D. Figure 4, shows the comparison between each treatment group for the full and missing datasets. Here, the “Control” group is used as the reference to which “Treatment” group is being compared. Of notice, the pairwise comparison has been set on the response scale (see Appendix for code details), because otherwise the comparison appears shifted and is not intuitively easy to relate to the original data.

With this correction in mind, the shaded regions over the confidence interval (where it does not cover 0) indicate the time interval where each group has a higher effect than the other. Notice that the shaded region between days 0 and  $\approx 2$  for the full dataset indicates that through that time, the “Control” group has higher  $\text{StO}_2$ , but as therapy progresses the effect is reversed and by  $\approx 3$  day it is the “Treatment” group the one that has greater  $\text{StO}_2$ . This would suggest that the effect of chemotherapy in the “Treatment” group becomes

significant after day 3 for the model used. Moreover, notice that although there is no actual measurement at day 3, the model is capable of providing an estimate of when the shift in  $\text{StO}_2$  occurs.

On the data with missing observations (Figure 3, D), the confidence intervals of the smooths overlap between days 0 and 3. Consequently, the smooth pairwise comparison (Figure 4, B) shows that there is not a significant difference between the groups during that period, but is still able to pick the change on day 3 as the full dataset smooth pairwise comparison.

In a sense, the pairwise smooth comparison is more informative than a *post-hoc p-value*. For biomedical studies, the smooth comparison is able to provide an estimate of *when* and by *how much* a biological process becomes significant. This is advantageous because it can help researchers gain insight on metabolic changes and other biological processes that can be worth examining, and can help refine the experimental design of future studies in order to obtain measurements at time points where a significant change might be expected.

## 6 Discussion

Biomedical longitudinal non-linear data is particularly challenging to analyze due to the likelihood of missing observations and different correlation structures in the data, which limit the use of rm-ANOVA. Although LMEMs have started to replace rm-ANOVA as the choice to analyze biomedical data, both methods yield biased estimates when they are used to fit non-linear data as we have visually demonstrated in Section 3.5. This “model misspecification” error, also is known as a “Type III” error [17] is particularly important because although the *p-value* is the common measure of statistical significance, the validity of its interpretation is determined by the agreement of the data and the model. Guidelines for statistical reporting in biomedical journals exist (the SAMPL guidelines) [56] but they have not been widely adopted and in the case of longitudinal data, we consider that researchers would benefit from reporting a visual assessment of the correspondence between the model fit and the data, instead of merely relying on a  $R^2$  value.

In this paper we have presented GAMs as a suitable method to analyze non-linear longitudinal data. It is interesting to note that although GAMs are a well established method to analyze temporal data in different fields (among which are palaeoecology, geochemistry, and ecology) [33,52] they are not routinely used in biomedical research despite an early publication from Hastie and Tibshirani that demonstrated their use in medical research [57]. This is possibly due to the fact that the theory behind GAMs can seem very different from that of rm-ANOVA and LMEMs, but the purpose of Section 4 is to demonstrate that at its core the theory quite simple: Instead of using a linear relationship to model the response (as rm-ANOVA and LMEMs do), GAMs use basis functions to build smooths that are capable of following non-linear trends in the data.

However, from a practical standpoint is equally important to demonstrate how GAMs are computationally implemented. We have provided an example on how GAMs can be fitted using simulated data that follows trends reported in biomedical literature [16] using R and the package *mgcv*[37] in Section 5, while a basic workflow for model selection is in the Appendix. One of the features of GAMs is that they go beyond a mere *p-value* to indicate differences between groups, and in turn provide a time-based estimate of shifts in the response that can be directly tied to biological values as the pairwise smooth comparisons in Figure 4 indicate. The model is therefore able to provide an estimate of significant change between the groups at time points where data was not directly measured even with missing data exists ( $\approx$  day 3 in Figure 4 A, B), which can be used by researchers as feedback on experiment design and to further evaluate important biological changes in future studies.

We have used R as the software of choice for this paper because not only provides a fully developed environment to fit GAMs, but also eases simulation (which is becoming increasingly used for exploratory statistical analysis and power calculations) and provides powerful and convenient methods of visualization, which are key aspects that biomedical researchers might need to consider to make their work reproducible. In this regard, reproducibility is still an issue in biomedical research [58,59], but it is becoming apparent that what other disciplines have experienced in this aspect is likely to impact sooner rather than later this field. Researchers need to plan on how they will make their data, code, and any other materials open and accessible as more journals and funding agencies recognize the importance and benefits of open science in biomedical

research. We have made all the data and code used in this paper accessible, and we hope that this will encourage other researchers to do the same with future projects.

## 7 Conclusion

We have presented GAMs as a method to analyze longitudinal biomedical data. Future directions of this work will include simulation-based estimations of statistical power using GAMs, as well as demonstrating the prediction capabilities of these models using large datasets. By making the data and code used in this paper accessible, we hope to address the need of creating and sharing reproducible work in biomedical research.

## 8 Acknowledgements

This work was supported by the National Science Foundation Career Award (CBET 1751554, TJM) and the Arkansas Biosciences Institute.

---



## 9 References

- [1] D. Roblyer, S. Ueda, A. Cerussi, W. Tanamai, A. Durkin, R. Mehta, D. Hsiang, J.A. Butler, C. McLaren, W.P. Chen, B. Tromberg, Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment, *Proceedings of the National Academy of Sciences of the United States of America*. 108 (2011) 14626–14631. <https://doi.org/10.1073/pnas.1013103108>.
- [2] A. Tank, H.M. Peterson, V. Pera, S. Tabassum, A. Leproux, T. O’Sullivan, E. Jones, H. Cabral, N. Ko, R.S. Mehta, B.J. Tromberg, D. Roblyer, Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens, *Breast Cancer Research*. 22 (2020) 1–10. <https://doi.org/doi:10.1186/s13058-020-01262-1>.
- [3] M.V. Pavlov, T.I. Kalganova, Y.S. Lyubimtseva, V.I. Plekhanov, G.Y. Golubyatnikov, O.Y. Ilyinskaya, A.G. Orlova, P.V. Subochev, D.V. Safonov, N.M. Shakhova, A.V. Maslennikova, Multimodal approach in assessment of the response of breast cancer to neoadjuvant chemotherapy, *Journal of Biomedical Optics*. 23 (2018). <https://doi.org/%7B10.1117/1.JBO.23.9.091410%7D>.
- [4] V. Demidov, A. Maeda, M. Sugita, V. Madge, S. Sadanand, C. Flueraru, I.A. Vitkin, Preclinical longitudinal imaging of tumor microvascular radiobiological response with functional optical coherence tomography, *Scientific Reports*. 8 (2018). <https://doi.org/%7B10.1038/s41598-017-18635-w%7D>.
- [5] G. Ritter, L. Cohen, C. Williams, E. Richards, L. Old, S. Welt, Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33, *Cancer Research*. 61 (2001) 6851–6859.
- [6] E.M. Roth, A.C. Goldberg, A.L. Catapano, A. Torri, G.D. Yancopoulos, N. Stahl, A. Brunet, G. Lecorps, H.M. Colhoun, Antidrug antibodies in atients treated with alirocumab, *New England Journal of Medicine*. 376 (2017) 1589–1590. <https://doi.org/%7B10.1056/NEJMc1616623%7D>.
- [7] J.D. Jones, H.E. Ramser, A.E. Woessner, K.P. Quinn, In vivo multiphoton microscopy detects longitudinal metabolic changes associated with delayed skin wound healing, *Communications Biology*. 1 (2018). <https://doi.org/%7B10.1038/s42003-018-0206-4%7D>.
- [8] M.C. Skala, A. Fontanella, L. Lan, J.A. Izatt, M.W. Dewhirst, Longitudinal optical imaging of tumor metabolism and hemodynamics, *Journal of Biomedical Optics*. 15 (2010). <https://doi.org/10.1117/1.3285584>.
- [9] G.J. Greening, K.P. Miller, C.R. Spainhour, M.D. Cato, T.J. Muldoon, Effects of isoflurane anesthesia on physiological parameters in murine subcutaneous tumor allografts measured via diffuse reflectance spectroscopy, *Biomedical Optics Express*. 9 (2018) 2871–2886. <https://doi.org/%7B10.1364/BOE.9.002871%7D>.
- [10] T.T. Sio, P.J. Atherton, B.J. Birkhead, D.J. Schwartz, J.A. Sloan, D.K. Seisler, J.A. Martenson, C.L. Loprinzi, P.C. Griffin, R.F. Morton, J.C. Anders, T.J. Stoffel, R.E. Haselow, R.B. Mowat, M.A.N. Wittich, J.D. Bearden III, R.C. Miller, Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]), *Supportive Care in Cancer*. 24 (2016) 3847–3855. <https://doi.org/%7B10.1007/s00520-016-3213-3%7D>.
- [11] J.I. Kamstra, P.U. Dijkstra, M. van Leeuwen, J.L.N. Roodenburg, J.A. Langendijk, Mouth opening in patients irradiated for head and neck cancer: A prospective repeated measures study, *Oral Oncology*. 51 (2015) 548–555. <https://doi.org/%7B10.1016/j.oraloncology.2015.01.016%7D>.
- [12] E.-J. Wagenmakers, M. Lee, T. Lodewyckx, G.J. Iverson, Bayesian versus frequentist inference, in: H. Hoijtink, I. Klugkist, P.A. Boelen (Eds.), *Bayesian Evaluation of Informative Hypotheses*, Springer New York, New York, NY, 2008: pp. 181–207. [https://doi.org/10.1007/978-0-387-09612-4\\_9](https://doi.org/10.1007/978-0-387-09612-4_9).

- [13] R. Gueorguieva, J.H. Krystal, Move over ANOVA - Progress in analyzing repeated-measures data and its reflection in papers published in the archives of general psychiatry, *Archives of General Psychiatry*. 61 (2004) 310–317. <https://doi.org/10.1001/archpsyc.61.3.310>.
- [14] P. Schober, T.R. Vetter, Repeated measures designs and analysis of longitudinal data: If at first you do not succeed-try, try again, *Anesthesia and Analgesia*. 127 (2018) 569–575. <https://doi.org/10.1213/ane.0000000000003511>.
- [15] J. Pinheiro, D. Bates, *Mixed-effects models in S and S-PLUS*, Springer Science & Business Media, 2006. <https://doi.org/https://doi.org/10.1007/b98882>.
- [16] K. Vishwanath, H. Yuan, W.T. Barry, M.W. Dewhirst, N. Ramanujam, Using optical spectroscopy to longitudinally monitor physiological changes within solid tumors, *Neoplasia*. 11 (2009) 889–900. <https://doi.org/10.1593/neo.09580>.
- [17] B. Dennis, J.M. Ponciano, M.L. Taper, S.R. Lele, Errors in statistical inference under model misspecification: evidence, hypothesis testing, and AIC, *Frontiers in Ecology and Evolution*. 7 (2019). <https://doi.org/%7B10.3389/fevo.2019.00372%7D>.
- [18] B. Wang, Z. Zhou, H. Wang, X.M. Tu, C. Feng, The p-value and model specification in statistics, *General Psychiatry*. 32 (2019). <https://doi.org/%7B10.1136/gpsych-2019-100081%7D>.
- [19] C. Liu, T.P. Cripe, M.-O. Kim, Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences, *Molecular Therapy*. 18 (2010) 1724–1730. <https://doi.org/10.1038/mt.2010.127>.
- [20] L.G. Halsey, D. Curran-Everett, S.L. Vowler, G.B. Drummond, The fickle  $p$  value generates irreproducible results, *Nature Methods*. 12 (2015) 179–185. <https://doi.org/%7B10.1038/nmeth.3288%7D>.
- [21] H. Abdi, Holm’s sequential Bonferroni procedure, *Encyclopedia of Research Design*. 1 (2010) 1–8. <https://doi.org/10.4135/9781412961288.n178>.
- [22] S. Nakagawa, A farewell to Bonferroni: the problems of low statistical power and publication bias, *Behavioral Ecology*. 15 (2004) 1044–1045. <https://doi.org/%7B10.1093/beheco/arh107%7D>.
- [23] A. Gelman, J. Hill, M. Yajima, Why we (usually) don’t have to worry about multiple comparisons, *Journal of Research on Educational Effectiveness*. 5 (2012) 189–211. <https://doi.org/%7B10.1080/19345747.2011.618213%7D>.
- [24] C. Albers, The problem with unadjusted multiple and sequential statistical testing, *Nature Communications*. 10 (2019). <https://doi.org/%7B10.1038/s41467-019-09941-0%7D>.
- [25] C. Ugrinowitsch, G.W. Fellingham, M.D. Ricard, Limitations of ordinary least squares models in analyzing repeated measures data, *Medicine and Science in Sports and Exercise*. 36 (2004) 2144–2148. <https://doi.org/10.1249/01.mss.0000147580.40591.75>.
- [26] H. Huynh, L.S. Feldt, Estimation of the Box correction for degrees of freedom from sample data in randomized block and split-plot designs, *Journal of Educational Statistics*. 1 (1976) 69–82. <https://doi.org/10.3102/10769986001001069>.
- [27] S.W. Greenhouse, S. Geisser, On methods in the analysis of profile data, *Psychometrika*. 24 (1959) 95–112. <https://doi.org/10.1007/bf02289823>.
- [28] N. Haverkamp, A. Beauducel, Violation of the sphericity assumption and its effect on type-I error rates in repeated measures ANOVA and multi-level linear models (MLM), *Frontiers in Psychology*. 8 (2017). <https://doi.org/%7B10.3389/fpsyg.2017.01841%7D>.

- [29] H. Keselman, J. Algina, R. Kowalchuk, The analysis of repeated measures designs: A review, *British Journal of Mathematical & Statistical Psychology*. 54 (2001) 1–20. <https://doi.org/10.1348/0007110011593577D>.
- [30] Jaykaran. Charan, N. Kantharia, How to calculate sample size in animal studies?, *Journal of Pharmacology and Pharmacotherapeutics*. 4 (2013) 303–306. <https://doi.org/10.4103/0976-500X.119726>.
- [31] D.J. Barr, R. Levy, C. Scheepers, H.J. Tily, Random effects structure for confirmatory hypothesis testing: Keep it maximal, *Journal of Memory and Language*. 68 (2013) 255–278. <https://doi.org/10.1016/j.jml.2012.11.0017D>.
- [32] N.L. Rose, H.D. Yang, S.D. Turner, G.L. Simpson, An assessment of the mechanisms for the transfer of lead and mercury from atmospherically contaminated organic soils to lake sediments with particular reference to Scotland, UK, *Geochimica Et Cosmochimica Acta*. 82 (2012) 113–135. <https://doi.org/10.1016/j.gca.2010.12.026>.
- [33] E.J. Pedersen, D.L. Miller, G.L. Simpson, N. Ross, Hierarchical generalized additive models in ecology: An introduction with mgcv, *PeerJ*. 7 (2019). <https://doi.org/10.7717/peerj.6876>.
- [34] G.L. Simpson, Modelling palaeoecological time series using generalised additive models, *Frontiers in Ecology and Evolution*. 6 (2018). <https://doi.org/10.3389/fevo.2018.00149>.
- [35] L. Yang, G. Qin, N. Zhao, C. Wang, G. Song, Using a generalized additive model with autoregressive terms to study the effects of daily temperature on mortality, *BMC Medical Research Methodology*. 12 (2012). <https://doi.org/10.1186/1471-2288-12-1657D>.
- [36] N. Beck, S. Jackman, Beyond linearity by default: Generalized additive models, *American Journal of Political Science*. (1998) 596–627.
- [37] S.N. Wood, *Generalized additive models: An introduction with R*, Second Edition, CRC Press LLC, Philadelphia, PA, 2017.
- [38] R Core Team, *R: A language and environment for statistical computing*, R Foundation for Statistical Computing, Vienna, Austria, 2020. <https://www.R-project.org/>.
- [39] S.N. Wood, N. Pya, B. Saeften, Smoothing parameter and model selection for general smooth models, *Journal of the American Statistical Association*. 111 (2016) 1548–1563. <https://doi.org/10.1080/01621459.2016.11809867D>.
- [40] B.T. West, K.B. Welch, A.T. Galecki, *Linear mixed models: A practical guide using statistical software*, second edition, Taylor & Francis, 2014. <https://books.google.com/books?id=hjT6AwAAQBAJ>.
- [41] R.D. Wolfinger, Heterogeneous variance: Covariance structures for repeated measures, *Journal of Agricultural, Biological, and Environmental Statistics*. 1 (1996) 205–230. <http://www.jstor.org/stable/1400366>.
- [42] R.E. Weiss, *Modeling longitudinal data*, Springer New York, 2005. [https://books.google.com/books?id=MQ/\\_bvWDPsEAC](https://books.google.com/books?id=MQ/_bvWDPsEAC).
- [43] S. Geisser, S.W. Greenhouse, An extension of Box’s results on the use of the  $F$  distribution in multivariate analysis, *The Annals of Mathematical Statistics*. 29 (1958) 885–891. <https://doi.org/10.1214/aoms/1177706545>.
- [44] S.E. Maxwell, H.D. Delaney, K. Kelley, *Designing experiments and analyzing data: A model comparison perspective*, third edition, Taylor & Francis, 2017. <https://books.google.com/books?id=NmFQDwAAQBAJ>.

- [45] G. Molenberghs, H. Thijs, I. Jansen, C. Beunckens, M. Kenward, C. Mallinckrodt, R. Carroll, Analyzing incomplete longitudinal clinical trial data, *Biostatistics*. 5 (2004) 445–464. <https://doi.org/10.1093/biostatistics/kxh001>.
- [46] J. Scheffer, Dealing with missing data, *Research Letters in the Information and Mathematical Sciences*. 3 (2002) 153–160.
- [47] R.F. Potthoff, G.E. Tudor, K.S. Pieper, V. Hasselblad, Can one assess whether missing data are missing at random in medical studies?, *Statistical Methods in Medical Research*. 15 (2006) 213–234. <https://doi.org/10.1191/0962280206sm448oa>.
- [48] Y. Ma, M. Mazumdar, S.G. Memtsoudis, Beyond repeated-measures analysis of variance advanced statistical methods for the analysis of longitudinal data in anesthesia research, *Regional Anesthesia and Pain Medicine*. 37 (2012) 99–105. <https://doi.org/10.1097/AAP.0b013e31823ebc74>.
- [49] J. Pinheiro, D. Bates, S. DebRoy, D. Sarkar, R Core Team, nlme: Linear and nonlinear mixed effects models, 2020. <https://CRAN.R-project.org/package=nlme>.
- [50] J.A. Nelder, R.W.M. Wedderburn, Generalized linear models, *Journal of the Royal Statistical Society. Series A (General)*. 135 (1972) 370–384. <http://www.jstor.org/stable/2344614>.
- [51] T. Hastie, R. Tibshirani, Generalized additive models: Some applications, *Journal of the American Statistical Association*. 82 (1987) 371–386. <https://doi.org/10.1080/01621459.1987.10478440>.
- [52] T.J. Hefley, K.M. Broms, B.M. Brost, F.E. Buderman, S.L. Kay, H.R. Scharf, J.R. Tipton, P.J. Williams, M.B. Hooten, The basis function approach for modeling autocorrelation in ecological data, *Ecology*. 98 (2017) 632–646. <https://doi.org/10.1002/ecy.1674>.
- [53] E.J. Wegman, I.W. Wright, Splines in statistics, *Journal of the American Statistical Association*. 78 (1983) 351–365. <https://doi.org/10.1080/01621459.1983.10477977>.
- [54] G.L. Simpson, Gratia: Graceful 'ggplot'-based graphics and other functions for GAMs fitted using 'mgcv', 2020. <https://CRAN.R-project.org/package=gratia>.
- [55] J. Harezlak, D. Ruppert, M.P. Wand, *Semiparametric Regression with R*, Springer New York, 2018. <https://doi.org/10.1007/978-1-4939-8853-2>.
- [56] T.A. Lang, D.G. Altman, Basic statistical reporting for articles published in Biomedical Journals: The “Statistical Analyses and Methods in the Published Literature” or the SAMPL Guidelines, *INTERNATIONAL JOURNAL OF NURSING STUDIES*. 52 (2015) 5–9. <https://doi.org/10.1016/j.ijnurstu.2014.09.006>.
- [57] T. Hastie, R. Tibshirani, Generalized additive models for medical research, *Statistical Methods in Medical Research*. 4 (1995) 187–196. <https://doi.org/10.1177/096228029500400302>.
- [58] C.G. Begley, J.P.A. Ioannidis, Reproducibility in Science Improving the Standard for Basic and Preclinical Research, *Circulation Research*. 116 (2015) 116–126. <https://doi.org/10.1161/CIRCRESAHA.114.303819>.
- [59] T.L. Weissgerber, O. Garcia-Valencia, V.D. Garovic, N.M. Milic, S.J. Winham, Meta-Research: Why we need to report more than 'Data were Analyzed by t-tests or ANOVA', *Elife*. 7 (2018) e36163. <https://doi.org/10.7554/eLife.36163>.

## A Code for Manuscript data

This section presents the code used to generate figures, models and simulated data from Sections 3 and 4 from the main manuscript.

## A.1 Compound symmetry and independent errors in linear and quadratic responses

This section simulated linear and quadratic data in the same manner as in Section 3.5. The linear simulations using Figure 5 show in panels A and D the simulated mean responses and individual data points. Panels C and G show a visual interpretation of “correlation” in the responses: In panel C, subjects that have a value of the random error  $\varepsilon$  either above or below the mean group response are more likely to have other observations that follow the same trajectory, thereby demonstrating correlation in the response. In panel G, because the errors are independent, there is no expectation that responses are likely to follow a similar pattern. Panels D and H show the predictions from the rm-ANOVA model.

The following code produces a more comprehensive exploration of Figure 1 in the main manuscript.

```
#####Section for calculations#####

## Example with linear response

#This function simulates data using a linear or quadratic mean response
  and each with correlated
#or uncorrelated errors. Each group has a different slope/concavity.
example <- function(n_time = 6, #number of time points
                    fun_type = "linear", #type of response
                    error_type = "correlated") {

  if (!(fun_type %in% c("linear", "quadratic")))
    stop('fun_type must be either "linear", or "quadratic"')
  if (!(error_type %in% c("correlated", "independent")))
    stop('fun_type must be either "correlated", or "independent"')

  x <- seq(1,6, length.out = n_time)

  #Create mean response matrix: linear or quadratic
  mu <- matrix(0, length(x), 2)
  # linear response
  if (fun_type == "linear") {
    mu[, 1] <- - (0.25*x)+2
    mu[, 2] <- 0.25*x+2
  } else {
    # quadratic response (non-linear)

    mu[, 1] <- -(0.25 * x^2) +1.5*x-1.25
    mu[, 2] <- (0.25 * x^2) -1.5*x+1.25
  }

  #create an array where individual observations per each time point for
    each group are to be stored. Currently using 10 observations per
    timepoint
  y <- array(0, dim = c(length(x), 2, 10))

  #Create array to store the "errors" for each group at each timepoint.
    The "errors" are the
  #between-group variability in the response.
  errors <- array(0, dim = c(length(x), 2, 10))
```

```

678 #create an array where 10 observations per each time point for each
679     group are to be stored
680
681 #The following cycles create independent or correlated responses. To
682     each value of mu (mean response per group) a randomly generated error
683     (correlated or uncorrelated) is added and thus the individual
684     response is created.
685 if (error_type == "independent") {
686     ## independent errors
687     for (i in 1:2) {
688         for (j in 1:10) {
689             errors[, i, j] <- rnorm(6, 0, 0.25)
690             y[, i, j] <- mu[, i] + errors[, i, j]
691         }
692     }
693 } else {
694     for (i in 1:2) {      # number of treatments
695         for (j in 1:10) { # number of subjects
696             # compound symmetry errors: variance covariance matrix
697             errors[, i, j] <- rmvn(1, rep(0, length(x)), 0.1 * diag(6) + 0.25
698                 * matrix(1, 6, 6))
699             y[, i, j] <- mu[, i] + errors[, i, j]
700         }
701     }
702 }
703
704
705 ## subject random effects
706
707 ## visualizing the difference between independent errors and compound
708     symmetry
709 ## why do we need to account for this -- overly confident inference
710
711 #labeling y and errors
712 dimnames(y) <- list(time = x,
713                     treatment = 1:2,
714                     subject = 1:10)
715
716 dimnames(errors) <- list(time = x,
717                          treatment = 1:2,
718                          subject = 1:10)
719
720 #labeling the mean response
721 dimnames(mu) <- list(time = x,
722                     treatment = 1:2)
723
724 #convert y, mu and errors to dataframes with time, treatment and
725     subject columns
726 dat <- as.data.frame.table(y,
727                             responseName = "y")
728 dat_errors <- as.data.frame.table(errors,
729                                   responseName = "errors")
730 dat_mu <- as.data.frame.table(mu,
731                               responseName = "mu")

```

```

732
733 #join the dataframes to show mean response and errors per subject
734 dat <- left_join(dat, dat_errors,
735                 by = c("time", "treatment", "subject"))
736 dat <- left_join(dat, dat_mu,
737                 by = c("time", "treatment"))
738 #add time
739 dat$time <- as.numeric(as.character(dat$time))
740 #label subjects per group
741 dat <- dat %>%
742   mutate(subject = factor(paste(subject,
743                                 treatment,
744                                 sep = "-")))
745
746
747 ## repeated measures ANOVA
748
749 fit_anova <- lm(y ~ time + treatment + time * treatment, data = dat)
750
751 #LMEM: time and treatment interaction model, compound symmetry
752 fit_lme <- lme(y ~ treatment + time + treatment:time,
753               data = dat,
754               random = ~ 1 | subject,
755               correlation = corCompSymm(form = ~ 1 | subject)
756             )
757
758 #create a prediction frame where the model can be used for plotting
759   purposes
760 pred_dat <- expand.grid(
761   treatment = factor(1:2),
762   time = unique(dat$time)
763 )
764
765 #add model predictions to the dataframe that has the simulated data
766 dat$pred_anova <- predict(fit_anova)
767 dat$pred_lmem <- predict(fit_lme)
768
769 #return everything in a list
770 return(list(
771   dat = dat,
772   pred_dat = pred_dat,
773   fit_anova=fit_anova,
774   fit_lme = fit_lme
775 ))
776 }
777 #####Section for plotting#####
778 #####
779 #This function will create the plots for either a "linear" or "quadratic"
780   response
781
782 plot_example <- function(sim_dat) {
783   ## Plot the simulated data (scatterplot)
784
785   p1 <- sim_dat$dat %>%

```

```

786 ggplot(aes(x = time,
787             y = y,
788             group = treatment,
789             color = treatment)
790         ) +
791     geom_point(show.legend=FALSE) +
792     labs(y='response')+
793     geom_line(aes(x = time,
794                  y = mu,
795                  color = treatment),
796              show.legend=FALSE) +
797     theme_classic() +
798     theme(plot.title = element_text(size = 30,
799                                     face = "bold"),
800           text=element_text(size=30))+
801     thm
802
803 #plot the simulated data with trajectories per each subject
804 p2 <- sim_dat$dat %>%
805     ggplot(aes(x = time,
806                y = y,
807                group = subject,
808                color = treatment)
809            ) +
810     geom_line(aes(size = "Subjects"),
811              show.legend = FALSE) +
812     # facet_wrap(~ treatment) +
813     geom_line(aes(x = time,
814                   y = mu,
815                   color = treatment,
816                   size = "Simulated Truth"),
817              lty = 1, show.legend = FALSE) +
818     labs(y='response')+
819     scale_size_manual(name = "Type", values=c("Subjects" = 0.5, "Simulated
820         Truth" = 3)) +
821     theme_classic()+
822     theme(plot.title = element_text(size = 30,
823                                     face = "bold"),
824           text=element_text(size=30))+
825     thm
826
827 #plot the errors
828 p3 <- sim_dat$dat %>%
829     ggplot(aes(x = time,
830                y = errors,
831                group = subject,
832                color = treatment)) +
833     geom_line(show.legend=FALSE) +
834     labs(y='errors')+
835     theme_classic()+
836     theme(plot.title = element_text(size = 30,
837                                     face = "bold"),
838           text=element_text(size=30))+
839     thm

```



```

840
841 #plot the model predictions for rm-ANOVA
842 p4 <- ggplot(sim_dat$dat,
843             aes(x = time,
844                 y = y,
845                 color = treatment)) +
846   geom_point(show.legend=FALSE)+
847   labs(y='response')+
848   geom_line(aes(y = predict(sim_dat$fit_anova),
849                       group = subject, size = "Subjects"),show.legend = FALSE)
850   +
851   geom_line(data = sim_dat$pred_dat,
852             aes(y = predict(sim_dat$fit_anova,
853                             level = 0,
854                             newdata = sim_dat$pred_dat),
855                 size = "Population"),
856             show.legend=FALSE) +
857   guides(color = guide_legend(override.aes = list(size = 2)))+
858   scale_size_manual(name = "Predictions",
859                     values=c("Subjects" = 0.5, "Population" = 3)) +
860   theme_classic() +
861   theme(plot.title = element_text(size = 30,
862                                   face = "bold"),
863         text=element_text(size=30))+
864   thm
865
866
867
868 #plot the LMEM predictions
869 p5 <- ggplot(sim_dat$dat,
870             aes(x = time,
871                 y = y,
872                 color = treatment)) +
873   geom_point()+
874   labs(y='response')+
875   geom_line(aes(y = predict(sim_dat$fit_lme),
876                       group = subject, size = "Subjects")) +
877   geom_line(data = sim_dat$pred_dat,
878             aes(y = predict(sim_dat$fit_lme,
879                             level = 0,
880                             newdata = sim_dat$pred_dat),
881                 size = "Population")) +
882   guides(color = guide_legend(override.aes = list(size = 2)))+
883   scale_size_manual(name = "Predictions",
884                     values=c("Subjects" = 0.5, "Population" = 3)) +
885   theme_classic() +
886   theme(plot.title = element_text(size = 30,
887                                   face = "bold"),
888         text=element_text(size=30))+
889   thm
890
891 return((p1+p3+p2+p4+p5)+plot_layout(nrow=1)+plot_annotation(tag_levels =
892   'A'))
893

```

```

894 }
895
896
897 txt<-18
898
899 #Store each plot in a separate object
900 A1<-plot_example(example(fun_type = "linear", error_type = "correlated"))
901
902 B1<-plot_example(example(fun_type = "linear", error_type = "independent"))
903
904 C1<-plot_example(example(fun_type = "quadratic", error_type = "correlated"
905   ))
906
907 D1<-plot_example(example(fun_type = "quadratic", error_type = "independent
908   "))

```




Figure 5: Simulated linear responses from two groups with correlated (top row) or independent (bottom row) errors using a rm-ANOVA model and a LMEM. A, F: Simulated data with known mean response and individual responses (points) showing the dispersion of the data. B, G: Generated errors showing the difference in the behavior of correlated and independent errors. C, H: Simulated data with thin lines representing individual trajectories. D, I: Estimations from the rm-ANOVA model for the mean group response. E, J: Estimations from the LMEM for the mean group response and individual responses (thin lines). In all panels, thick lines are the predicted mean response per group, thin lines are the random effects for each subject and points represent the original raw data. Both rm-ANOVA and the LMEM are able to capture the trend of the data.

910 For the quadratic response case, Figure 6 shows the simulated responses using compound symmetry and  
 911 independent errors.




Figure 6: Simulated quadratic responses from two groups with correlated (top row) or independent (bottom row) errors using a rm-ANOVA model and a LMEM. A, F: Simulated data with known mean response and individual responses (points) showing the dispersion of the data. B, G: Generated errors showing the difference in the behavior of correlated and independent errors. C, H: Simulated data with thin lines representing individual trajectories. D, I: Estimations from the rm-ANOVA model for the mean group response. E, J: Estimations from the LMEM for the mean group response and individual responses (thin lines). In all panels, thick lines are the predicted mean response per group, thin lines are the random effects for each subject and points represent the original raw data. Both rm-ANOVA and the LMEM are not able to capture the changes in each group over time.

## 912 A.2 Basis functions and GAMs

913 This code produces Figure 2 from the main manuscript. Briefly, a non-linear (quadratic) response is simulated  
 914 a gam model is fitted and the basis are extracted in order to explain how the smooth is constructed. The  
 915 code for data simulation is used again here for the sake of keeping the same structure, although the data  
 916 can be simulated in a more simple fashion.

```
917 #generate the response: the same initial procedure from the previous
918 section to simulate
919 #the response
920 set.seed(1)
921 n_time = 6
```

```

923 x <- seq(1,6, length.out = n_time)
924 mu <- matrix(0, length(x), 2)
925 mu[, 1] <- -(0.25 * x^2) +1.5*x-1.25 #mean response
926 mu[, 2] <- (0.25 * x^2) -1.5*x+1.25 #mean response
927 y <- array(0, dim = c(length(x), 2, 10))
928 errors <- array(0, dim = c(length(x), 2, 10))
929 for (i in 1:2) { # number of treatments
930   for (j in 1:10) { # number of subjects
931     # compound symmetry errors
932     errors[, i, j] <- rmvn(1, rep(0, length(x)), 0.1 * diag(6) + 0.25
933       * matrix(1, 6, 6))
934     y[, i, j] <- mu[, i] + errors[, i, j]
935   }
936 }
937
938 #label each table
939 dimnames(y) <- list(time = x, treatment = 1:2, subject = 1:10)
940 dimnames(errors) <- list(time = x, treatment = 1:2, subject = 1:10)
941 dimnames(mu) <- list(time = x, treatment = 1:2)
942
943 #Convert to dataframes with subject, time and group columns
944 dat <- as.data.frame.table(y, responseName = "y")
945 dat_errors <- as.data.frame.table(errors, responseName = "errors")
946 dat_mu <- as.data.frame.table(mu, responseName = "mu")
947 dat <- left_join(dat, dat_errors, by = c("time", "treatment", "subject"))
948 dat <- left_join(dat, dat_mu, by = c("time", "treatment"))
949 dat$time <- as.numeric(as.character(dat$time))
950
951 #label subject per group
952 dat <- dat %>%
953   mutate(subject = factor(paste(subject, treatment, sep = "-")))
954
955 #extract "Group 1" to fit the GAM
956 dat<-subset(dat,treatment==1)
957 #keep just the response and timepoint columns
958 dat<-dat[,c('y','time')]
959
960 #GAM model of time, 5 knots
961 gm<-gam(y~s(time,k=5),data=dat)
962
963 #model_matrix (also known as) 'design matrix'
964 #will contain the smooths used to create model 'gm'
965 model_matrix<-as.data.frame(predict(gm,type='lpmatrix'))
966
967
968 time<-c(1:6)
969
970 basis<-model_matrix[1:6,] #extracting basis (because the values are
971   repeated after every 6 rows)
972 #basis<-model_matrix[1:6,-1] #extracting basis
973 colnames(basis)[colnames(basis)=="(Intercept)"]<- "s(time).0"
974 basis<-basis %>% #pivoting to long format
975   pivot_longer(
976     cols=starts_with("s")

```

```

977   )%>%
978   arrange(name) #ordering
979
980 #length of dataframe to be created: number of knots by number of
981   timepoints (minus 1 for the intercept that we won't plot)
982 ln<-6*(length(coef(gm)))
983
984 basis_plot<-data.frame(Basis=integer(ln),
985                        value_orig=double(ln),
986                        time=integer(ln),
987                        cof=double(ln)
988 )
989
990 basis_plot$time<-rep(time) #pasting timepoints
991 basis_plot$Basis<-factor(rep(c(1:5),each=6)) #pasting basis number values
992 basis_plot$value_orig<-basis$value #pasting basis values
993 basis_plot$cof<-rep(coef(gm)[1:5],each=6) #pasting coefficients
994 basis_plot<-basis_plot%>%
995   mutate(mod_val=value_orig*cof) #the create the predicted values the
996   bases need to be
997 #multiplied by the coefficients
998
999 #creating labeller to change the labels in the basis plots
1000
1001 basis_names<-c(
1002   '1'="Intercept",
1003   '2'="1",
1004   '3'="2",
1005   '4'="3",
1006   '5'="4"
1007 )
1008
1009 #calculating the final smooth by aggregating the basis functions
1010
1011 smooth<-basis_plot%>%
1012   group_by(time)%>%
1013   summarize(smooth=sum(mod_val))
1014
1015
1016 #original basis
1017 sz<-1
1018 p11<-ggplot(basis_plot,
1019             aes(x=time,
1020                 y=value_orig,
1021                 colour=as.factor(Basis)
1022             )
1023             )+
1024   geom_line(size=sz,
1025             show.legend=FALSE)+
1026   geom_point(size=sz+1,
1027              show.legend = FALSE)+
1028   labs(y='Basis functions')+
1029   facet_wrap(~Basis,
1030              labeller = as_labeller(basis_names)

```

```

1031         )+
1032     theme_classic()+
1033     thm
1034
1035
1036 #penalized basis
1037 p12<-ggplot(basis_plot,
1038             aes(x=time,
1039                 y=mod_val,
1040                 colour=as.factor(Basis)
1041             )
1042         )+
1043     geom_line(show.legend = FALSE,
1044              size=sz)+
1045     geom_point(show.legend = FALSE,
1046               size=sz+1)+
1047     labs(y='Penalized \n basis functions')+
1048     scale_y_continuous(breaks=seq(-1,1,1))+
1049     facet_wrap(~Basis,
1050               labeller=as_labeller(basis_names)
1051             )+
1052     theme_classic()+
1053     thm
1054
1055 #heatmap of the coefficients
1056 x_labels<-c("Intercept","1","2","3","4")
1057 p13<-ggplot(basis_plot,
1058             aes(x=Basis,
1059                 y=Basis))+
1060     geom_tile(aes(fill = cof),
1061              colour = "black") +
1062     scale_fill_gradient(low = "white",
1063                        high = "#B50A2AFF")+ #color picked from KikiMedium
1064     labs(x='Basis',
1065          y='Basis')+
1066     scale_x_discrete(labels=x_labels)+
1067     geom_text(aes(label=round(cof,2)),
1068              size=7,
1069              show.legend = FALSE)+
1070     theme_classic()+
1071     theme(legend.title = element_blank())
1072
1073 #plotting simulated datapoints and smooth term
1074 p14<-ggplot(data=dat,
1075             aes(x=time,y=y))+
1076     geom_point(size=sz+1)+
1077     labs(y='Simulated \n response')+
1078     geom_line(data=smooth,
1079              aes(x=time,
1080                  y=smooth),
1081              color="#6C581DFF",
1082              size=sz+1)+
1083     theme_classic()
1084

```

```

1085
1086 #Combining all
1087 b_plot<-p11+p13+p12+p14+plot_annotation(tag_levels='A')&
1088   theme(
1089     text=element_text(size=18)
1090   )
1091

```




Figure 7: Basis functions for a single smoother for time with five knots. A: Basis functions for a single smoother for time for the simulated data of Group 1 from Figure 2, the intercept basis is not shown. B: Matrix for basis function weights. Each basis function is multiplied by a coefficient which can be positive or negative. The coefficient determines the overall effect of each basis in the final smoother. C: Weighted basis functions. Each of the four basis functions of panel A has been weighted by the corresponding coefficient shown in Panel B, note the corresponding increase (or decrease) of each basis. D: Smoother for time and original data points. The smoother (line) is the result of the sum of each penalized basis function at each time point, with simulated values for the group shown as points.

## B Longitudinal biomedical data simulation and GAMs

This section describes how to fit GAMs to longitudinal data using simulated data. First, data is simulated according to Section 5, where reported data of oxygen saturation ( $\text{StO}_2$ ) in tumors under either chemotherapy or saline control is used as a starting point to generate individual responses in each group.

```

set.seed(1)

```

```

1098 #Dataframe that contains the original reported trends
1099 dat<-tibble(St02=c(4,27,3,2,0.5,7,4,50,45,56),
1100             Day=rep(c(0,2,5,7,10),times=2),
1101             Group=as.factor(rep(c("Control","Treatment"),each=5))
1102             )
1103
1104
1105 ## plot the mean response
1106 f1<-ggplot(dat,
1107            aes(x = Day,
1108                y = St02,
1109                color = Group)) +
1110    geom_line(size=1,
1111              show.legend = FALSE)+
1112    geom_point(show.legend = FALSE,
1113              size=1.5,
1114              alpha=0.5)+
1115    labs(y=expression(paste(St0[2],
1116                            ' (real)')))+
1117    theme_classic()+
1118    thm+
1119    scale_x_continuous(breaks=c(0,5,10))+
1120    scale_y_continuous(breaks=c(0,40))+
1121    plot_layout(tag_level = 'new')+
1122    theme(
1123      plot.background = element_rect(fill = "transparent",
1124                                      color = NA),
1125      axis.text=element_text(size=14)
1126    )
1127
1128
1129 #This function simulates data for the tumor data using default parameters
1130 #of 10 observations per time point,and Standard deviation (sd) of 5%.
1131 #Because physiologically St02 cannot go below 0%, data is generated with
1132 #a cutoff value of 0.0001 (the "St02_sim")
1133
1134 simulate_data <- function(dat, n = 10, sd = 5) {
1135   dat_sim <- dat %>%
1136     slice(rep(1:n(), each = n)) %>%
1137     group_by(Group, Day) %>%
1138     mutate(
1139       St02_sim = pmax(rnorm(n, St02, sd), 0.0001),
1140       subject=rep(1:10),
1141       subject=factor(paste(subject, Group, sep = "-"))
1142     ) %>%
1143     ungroup()
1144
1145   return(dat_sim)
1146 }
1147
1148
1149 #subject = factor(paste(subject, treatment, sep = "-"))
1150 n <- 10 #number of observations
1151 sd <- 10 #approximate sd from paper

```



```

1152 df <- 6
1153 dat_sim <- simulate_data(dat, n, sd)
1154
1155 #plotting simulated data
1156 f2<-ggplot(dat_sim,
1157            aes(x = Day,
1158                y = StO2_sim,
1159                color = Group)) +
1160   geom_point(show.legend=FALSE,
1161             size=1.5,
1162             alpha=0.5)+
1163   stat_summary(aes(y = StO2_sim,
1164                   group=Group),
1165               fun=mean, geom="line",
1166               size=1,
1167               show.legend = FALSE)+
1168   labs(y=expression(atop(StO2 [2],
1169                          '(simulated)')))+
1170   theme_classic()+
1171   theme(
1172     axis.text=element_text(size=22)
1173   )+
1174   thm+
1175   scale_x_continuous(breaks=c(0,2,5,7,10))
1176

```

---

## 1177 B.1 A basic Workflow for GAMs

1178 This section shows a basic workflow to fit a series of increasingly complex GAMs to the simulated data from  
 1179 the previous section. Graphical and parameter diagnostics for goodness of fit are discussed, as well as model  
 1180 comparison via AIC (Aikake Information Criterion).

### 1181 B.1.1 First model

1182 The first model fitted to the data is one that only accounts for different smooths by day. The model syntax  
 1183 specifies that `gam_00` is the object that will contain all the model information, and that the model attempts  
 1184 to explain changes in `StO2_sim` (simulated StO<sub>2</sub>) using a smooth per `Day`. The model will use 5 knots (`k=5`)  
 1185 for the smooth. The smooth is constructed by default using thin plate regression splines. The smoothing  
 1186 parameter estimation method used is the restricted maximum likelihood (REML).

```

1187 gam_00<-gam(StO2_sim ~ s(Day, k = 5),
1188            method='REML',
1189            data = dat_sim)
1190
1191

```

---

1192 To obtain model diagnostics, two methodologies are to be used: 1) graphical diagnostics, and 2) a model  
 1193 check. In the first case, the functions `appraise` and `draw` from the package *gratia* can be used to obtain  
 1194 a single output with all the graphical diagnostics. For model check, the functions `gam.check` and `summary`  
 1195 from *mgcv* provide detailed information about the model fit and its parameters.





Figure 8: Graphical diagnostics for the first GAM model. Left: Graphical diagnostics provided by the function `appraise` from the package *gratia*. Right: Fitted smooth for the model, provided by the function `draw`.

**B.1.1.1 Graphical diagnostics** From the output of the function `appraise` in Figure 8, the major indicators of concern about the model are the QQ plot of residuals and the histogram of residuals. The QQ plot shows that the errors are not reasonably located along the  $45^\circ$  line (which indicates normality), as there are multiple points that deviate from the trend, specially in the tails. The histogram also shows that the variation (residuals) is not following the assumption of a normal distribution.

The `draw` function permits to plot the smooths as `ggplot2` objects, which eases subsequent manipulation, if desired. Because model `gam_00` specifies only one smooth for the time covariate (Day), the plot only contains only one smooth. Note that the smooth shows an almost linear profile.

**B.1.1.2 Model check**

```
#need to add figure number and caption
gam.check(gam_00)
```



```

1208
1209
1210 ##
1211 ## Method: REML   Optimizer: outer newton
1212 ## full convergence after 5 iterations.
1213 ## Gradient range [-0.0003727881,-6.621452e-07]
1214 ## (score 444.0118 & scale 450.6638).
1215 ## Hessian positive definite, eigenvalue range [0.3881695,49.00676].
1216 ## Model rank = 5 / 5
1217 ##
1218 ## Basis dimension (k) checking results. Low p-value (k-index<1) may
1219 ## indicate that k is too low, especially if edf is close to k'.
1220 ##
1221 ##           k'   edf k-index p-value
1222 ## s(Day) 4.00 2.11    0.36 <2e-16 ***
1223 ## ---
1224 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1225

```

```

1226
1227 summary(gam_00)
1228

```

```

1229 ##
1230 ##
1231 ## Family: gaussian
1232 ## Link function: identity
1233 ##
1234 ## Formula:
1235 ## StO2_sim ~ s(Day, k = 5)
1236 ##
1237 ## Parametric coefficients:

```

```

1238 ##           Estimate Std. Error t value Pr(>|t|)
1239 ## (Intercept)    22.967      2.123   10.82  <2e-16 ***
1240 ## ---
1241 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1242 ##
1243 ## Approximate significance of smooth terms:
1244 ##           edf Ref.df      F  p-value
1245 ## s(Day)  2.114   2.565  7.633 0.000517 ***
1246 ## ---
1247 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1248 ##
1249 ## R-sq.(adj) =  0.153   Deviance explained = 17.2%
1250 ## -REML = 444.01   Scale est. = 450.66      n = 100
1251

```

1252 Special attention must be paid to the ‘k-index’ from `gam.check`. This parameter indicates if the basis  
1253 dimension of the smooth is adequate, i.e., it checks that the basis used to create the smooth are adequate  
1254 to capture the trends in the data. If the model is not adequately capturing the trends in the data, this is  
1255 indicated by a low k-index value ( $<1$ ). From the output, it can be seen that the k-index is 0.36, which  
1256 indicates that the model is not capturing the variability in the data. The `edf` (effective degrees of freedom)  
1257 is an indicator of the complexity of the smooth. Here the complexity of the smooth is comparable to that of  
1258 a 4th degree polynomial.

1259 From the `summary` function, information about the assumed distribution of the errors (Gaussian in this  
1260 case) and the link function can be obtained. The link function is ‘identity’ as the model does not make  
1261 any transformation on the predictors. The ‘significance of smooth terms’ *p-value* indicates if each smooth  
1262 is adding significance to the model. Here, the *p-value* is low but we have seen that there are issues with  
1263 the model from the previous outputs. Finally, the ‘deviance explained’ indicates how much of the data the  
1264 model is able to capture, which in this case corresponds to  $\approx 17\%$ .


## 1265 B.1.2 Second model

1266 The major flaw of `gam_00` is that this model is not taking into account the fact that the data is nested in  
1267 groups. The next iteration is a model where a different smooth of time (Day) is assigned for each group  
1268 using `by=Group` in the model syntax.

```

1269
1270 gam_01<-gam(St02_sim ~ s(Day, by=Group, k = 5),
1271             method='REML',
1272             data = dat_sim)
1273
1274 gam.check(gam_01)
1275

```



```

1276
1277
1278 ##
1279 ## Method: REML   Optimizer: outer newton
1280 ## full convergence after 7 iterations.
1281 ## Gradient range [-5.51754e-05,2.671715e-06]
1282 ## (score 423.3916 & scale 280.8777).
1283 ## Hessian positive definite, eigenvalue range [0.3162258,48.5557].
1284 ## Model rank = 9 / 9
1285 ##
1286 ## Basis dimension (k) checking results. Low p-value (k-index<1) may
1287 ## indicate that k is too low, especially if edf is close to k'.
1288 ##
1289 ##           k'   edf k-index p-value
1290 ## s(Day):GroupControl  4.00 3.39    0.43 <2e-16 ***
1291 ## s(Day):GroupTreatment 4.00 3.23    0.43 <2e-16 ***
1292 ## ---
1293 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1294

```

```

1295
1296 summary(gam_01)
1297
1298 ##
1299 ## Family: gaussian
1300 ## Link function: identity
1301 ##
1302 ## Formula:
1303 ## St02_sim ~ s(Day, by = Group, k = 5)
1304 ##
1305

```

```

1306 ## Parametric coefficients:
1307 ##           Estimate Std. Error t value Pr(>|t|)
1308 ## (Intercept)    22.967      1.676    13.7   <2e-16 ***
1309 ## ---
1310 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1311 ##
1312 ## Approximate significance of smooth terms:
1313 ##           edf Ref.df      F p-value
1314 ## s(Day):GroupControl  3.392  3.794  3.817  0.0304 *
1315 ## s(Day):GroupTreatment 3.229  3.682 21.174 <2e-16 ***
1316 ## ---
1317 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1318 ##
1319 ## R-sq.(adj) =  0.472   Deviance explained = 50.8%
1320 ## -REML = 423.39   Scale est. = 280.88      n = 100
1321

```

1322 Diagnostics for this model indicate that the k-index is still below 1 (0.43 from `gam.check`), and that the  
1323 residuals are still not following a normal distribution (Figure 9). Moreover, the smooths (plotted via the  
1324 `draw()` function) appear with a fairly linear profile, which indicates they are still not capturing the trends  
1325 observed in the data. From `summary()`, the deviance explained by the model is  $\approx 51\%$ .




Figure 9: Graphical diagnostics for the second GAM model. Left: Graphical diagnostics provided by the function `appraise` from the package *gratia*. Right: Fitted smooth for the model, provided by the function `draw`.


### 1326 B.1.3 Third model

1327 Model `gam_00` was built for didactic purposes to cover the simplest case, but it does not account for the  
1328 nesting of the data by Group, which is apparent from the type of smooth fitted, the model diagnostics, and,  
1329 the low variance explained by the model. On the other hand, `gam_01` takes into account the nesting within  
1330 each group and provides better variance explanation, but as indicated in Section 5, in order to differentiate  
1331 between each group a parametric term needs to be added to the model for the interaction of *Day* and *Group*.

```

1332 #GAM for StO2
1333
1334
1335 m1 <- gam(StO2_sim ~ Group+s(Day, by = Group, k = 5),
1336           method='REML',
1337           data = dat_sim)
1338
1339 gam.check(m1)
1340

```



```

1341
1342 ##
1343 ## Method: REML   Optimizer: outer newton
1344 ## full convergence after 10 iterations.
1345 ## Gradient range [-8.164307e-08,1.500338e-08]
1346 ## (score 355.8554 & scale 64.53344).
1347 ## Hessian positive definite, eigenvalue range [1.174841,48.08834].
1348 ## Model rank = 10 / 10
1349 ##
1350 ##
1351 ## Basis dimension (k) checking results. Low p-value (k-index<1) may
1352 ## indicate that k is too low, especially if edf is close to k'.
1353 ##
1354 ##           k'   edf k-index p-value
1355 ## s(Day):GroupControl  4.00 3.87   1.02   0.59
1356 ## s(Day):GroupTreatment 4.00 3.88   1.02   0.54
1357

```

```

1358 summary(m1)
1359
1360

```

```

1361 ##
1362 ##
1363 ## Family: gaussian
1364 ## Link function: identity
1365 ##
1366 ## Formula:
1367 ## St02_sim ~ Group + s(Day, by = Group, k = 5)
1368 ##
1369 ## Parametric coefficients:
1370 ##               Estimate Std. Error t value Pr(>|t|)
1371 ## (Intercept)      9.084      1.136   7.996 4.09e-12 ***
1372 ## GroupTreatment    27.766      1.607  17.282 < 2e-16 ***
1373 ## ---
1374 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1375 ##
1376 ## Approximate significance of smooth terms:
1377 ##               edf Ref.df   F p-value
1378 ## s(Day):GroupControl  3.873  3.990 17.57 <2e-16 ***
1379 ## s(Day):GroupTreatment 3.879  3.991 89.33 <2e-16 ***
1380 ## ---
1381 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1382 ##
1383 ## R-sq.(adj) =  0.879   Deviance explained = 88.9%
1384 ## -REML = 355.86   Scale est. = 64.533   n = 100
1385

```

1386 The resulting model is `m1`, which is the model fitted in the main manuscript. By using `appraise()` and `draw`  
1387 on this model (Figure 10) we see that the trend on the QQ plot has improved, the histogram of the residuals  
1388 appears to be reasonably distributed, and the smooths are capturing the trend of the data within each group.  
1389 From `gam.check`, the k-index is now at an acceptable value ( $\approx 1.02$ ), and `summary` now indicates that the  
1390 model is able to capture 89% of the variance in the data.




Figure 10: Graphical diagnostics for the final GAM model. Left: Graphical diagnostics provided by the function `appraise` from the package *gratia*. Right: Fitted smooths for the model, provided by the function `draw`.



## B.1.4 Comparing models via AIC

One final comparison that can be made for model selection involves the use of the Aikake Information Criterion (AIC). This metric is used to estimate information loss, which we want to minimize with an appropriate model. Therefore, when 2 or more models are compared, the model with lower AIC is preferred. In R, the comparison is done using the `AIC` function.

```
AIC(gam_00, gam_01, m1)
```

	##		df	AIC
	##	gam_00	4.564893	900.8257
	##	gam_01	9.476137	858.6051
	##	m1	10.980983	712.2067

The output in this case is expected: model `m1` has a lower AIC (712.46) whereas the initial two models have higher AICs (900 and 858). The AIC should not be considered as the only estimator of model quality, instead to be used as complimentary information to the graphical diagnostics and model checks described above.

**B.1.4.1 Pairwise comparisons of smooth confidence intervals** The estimation of significant differences between each treatment group can be achieved via pairwise comparisons of the smooth confidence intervals as described in section 5.3. In this case, the “design matrix” is used to estimate the pairwise comparisons (see main manuscript for details and associated references). Briefly, the “design matrix” (also known as the “Xp matrix”) from the selected model (`m1`) is used to calculate a 95% confidence interval of the difference between the smooth terms for each group. This approach allows to estimate the time intervals where a significant difference exists between the groups (confidence interval above or below 0). **All pairwise comparisons in this paper have been centered at the response scale to ease interpretation .**

```
##Pairwise comparisons
pdat <- expand.grid(Day = seq(0, 10, length = 400),
                  Group = c('Control', 'Treatment'))

##matrix that contains the basis functions evaluated at the points in pdat
xp <- predict(m1, newdata = pdat, type = 'lpmatrix')

#Find columns in xp where the name contains "Control"
c1 <- grepl('Control', colnames(xp))

#Find columns in xp where the name contains 'Treatment'
c2 <- grepl('Treatment', colnames(xp))

#Find rows in pdat that correspond to either 'Control' or 'Treatment'
r1 <- with(pdat, Group == 'Control')
r2 <- with(pdat, Group == 'Treatment')

# In xp: find the rows that correspond to Control or Treatment, those that
do not match will be
#set to zero. Then, subtract the values from the rows corresponding
to 'Control' from those that correspond
#to 'Treatment'
X <- xp[r1, ] - xp[r2, ]

## remove columns that do not contain name 'Control' or 'Treatment'
```

```

1444 X[, ! (c1 | c2)] <- 0
1445 ## zero out the parametric cols, those that do not contain in the
1446 characters 's('
1447 #X[, !grepl('^s\\(', colnames(xp))] <- 0
1448
1449 #Multiply matrix by model coefficients. X has (p,n) (rows, columns)
1450 and the coefficient matrix has
1451 #dimensions (n,1). The resulting matrix has dimensions (p,1)
1452 dif <- X %>% coef(m1)
1453
1454 #comp<-test %>% coef(gam1)[3:10]
1455
1456 #Calculate standard error for the computed differences using the variance-
1457 covariance matrix
1458 #of the model
1459 se <- sqrt(rowSums((X %>% vcov(m1, unconditional = FALSE)) * X))
1460 crit <- qt(0.05/2, df.residual(m1), lower.tail = FALSE)
1461 #upper limits
1462 upr <- dif + (crit * se)
1463 #lower limits
1464 lwr <- dif - (crit * se)
1465 #put all components in a dataframe for plotting
1466 comp1<-data.frame(pair = paste('Control', 'Treatment', sep = '-'),
1467                   diff = dif,
1468                   se = se,
1469                   upper = upr,
1470                   lower = lwr)
1471
1472
1473
1474 #add time point sequence
1475 comp_St02 <- cbind(Day = seq(0, 10, length = 400),
1476                   rbind(comp1))
1477
1478 #use function from the pairwise comparison plot in the manuscript to get
1479 the shaded regions
1480
1481 my_list<-pairwise_limits(comp_St02)
1482
1483 #plot the difference
1484 c1<-ggplot(comp_St02, aes(x = Day, y = diff, group = pair)) +
1485   #shaded region
1486   annotate("rect",
1487           xmin =my_list$init1, xmax =my_list$final1,ymin=-Inf,ymax=
1488             Inf,
1489           fill='#30123BFF',
1490           alpha = 0.5,
1491           ) +
1492   annotate("text",
1493           x=1.5,
1494           y=-10,
1495           label="Control",size=10
1496           )+
1497   #shaded region

```

```

1498   annotate("rect",
1499           xmin =my_list$init2, xmax =my_list$final2,ymin=-Inf,ymax=Inf,
1500           fill='#7A0403FF',
1501           alpha = 0.5
1502         ) +
1503   annotate("text",
1504           x=6,
1505           y=-10,
1506           label="Treatment",
1507           size=10
1508         )+
1509   #ribbon for difference confidence interval
1510   geom_ribbon(aes(ymin = lower, ymax = upper),
1511             alpha = 0.5,
1512             fill='#DB3A07FF') +
1513   geom_line(color='black',size=1) +
1514   geom_line(data=comp_St02,aes(y=0),size=0.5)+
1515   facet_wrap(~ pair) +
1516   theme_classic()+
1517   labs(x = 'Days', y = expression(paste('Difference in St0'[2] )))+
1518   scale_x_continuous(breaks=c(0,2,5,7,10))+
1519   theme(
1520     text=element_text(size=18),
1521     legend.title=element_blank()
1522   )
1523 )

```




Figure 11: Smooth pairwise comparisons for model `m1` using a 95% confidence interval for the difference between smooths. The comparison is centered at the response scale. Shaded regions indicate time intervals where each treatment group has a non-zero effect.

1524 Of notice, a convenient wrapper for the function described above exists in the package `gratia`. In this  
1525 package, `difference_smooths` is a function that makes the comparisons and produces Figure 11 when is

used on a fitted model. The function syntax and an example can be found at:

<https://cran.r-project.org/web/packages/gratia/gratia.pdf>

Keep in mind that this function **does not** center the pairwise comparison at the response scale, so it has to be shifted in order to be compared to the raw data.

## C GAM and Linear model plots and Missing data

This section covers the code used to generate Figure 3, where the simulated data, fit of the “final” GAM (`m1`), linear model and GAM on data with missing observations are presented. Note that panel A in Figure 3 and the inlet are generated in the code chunk where the data is simulated in Section B, and are called later to build the figure.

### C.1 GAM and Linear model plots

This code chunk creates panels B and D in Figure 3. Note that this code uses the final GAM from the previous section (`m1`), so the simulated data and the model should be generated before running this section.

```
#linear model
lm1<-lm(St02_sim ~ Day + Group + Day * Group, data = dat_sim)

#creates a dataframe using the length of the covariates for the GAM
gam_predict <- expand_grid(Group = factor(c("Control", "Treatment")),
                          Day = seq(0, 10, by = 0.1),
                          subject=factor(rep(1:10)))

#creates a dataframe using the length of the covariates for rm-ANOVA
lm_predict<-expand_grid(Group = factor(c("Control", "Treatment")),
                        Day = c(0:10),
                        subject=factor(rep(1:10)),
                        )
lm_predict$subject<-factor(paste(lm_predict$subject, lm_predict$Group, sep
= "-"))

#adds the predictions to the grid and creates a confidence interval for
GAM
gam_predict<-gam_predict%>%
  mutate(fit = predict(m1,gam_predict,se.fit = TRUE,type='response')$fit
,
        se.fit = predict(m1, gam_predict,se.fit = TRUE,type='response')
        $se.fit)

#using lm
lm_predict<-lm_predict%>%
  mutate(fit = predict(lm1,lm_predict,se.fit = TRUE,type='response')$fit
,
        se.fit = predict(lm1, lm_predict,se.fit = TRUE,type='response')
        $se.fit)

#plot smooths and confidence interval for GAM
f3<-ggplot(data=dat_sim, aes(x=Day, y=St02_sim, group=Group)) +
```

```

1573     geom_point(aes(color=Group),size=1.5,alpha=0.5,show.legend = FALSE)+
1574     geom_ribbon(aes( x=Day,ymin=(fit - 2*se.fit),
1575                     ymax=(fit + 2*se.fit),
1576                     fill=Group
1577                     ),
1578                 alpha=0.3,
1579                 data=gam_predict,
1580                 show.legend=FALSE,
1581                 inherit.aes=FALSE) +
1582     geom_line(aes(y=fit,
1583                  color=Group),
1584              size=1,data=gam_predict,
1585              show.legend = FALSE)+
1586     #facet_wrap(~Group)+
1587     labs(y=expression(atop(St0[2], 'complete')))+
1588     scale_x_continuous(breaks=c(0,2,5,7,10))+
1589     theme_classic()+
1590     theme(
1591       axis.text=element_text(size=22)
1592     )+
1593     thm+
1594     thm1
1595
1596 #plot linear fit for rm-ANOVA
1597 f4<-ggplot(data=dat_sim, aes(x=Day, y=St02_sim, group=Group)) +
1598     geom_point(aes(color=Group),size=1.5,alpha=0.5,show.legend = FALSE)+
1599     geom_ribbon(aes( x=Day,ymin=(fit - 2*se.fit),
1600                     ymax=(fit + 2*se.fit),fill=Group),
1601                 alpha=0.3,
1602                 data=lm_predict,
1603                 show.legend = FALSE,
1604                 inherit.aes=FALSE) +
1605     geom_line(aes(y=fit,
1606                  color=Group),
1607              size=1,data=lm_predict,
1608              show.legend = FALSE)+
1609     #facet_wrap(~Group)+
1610     labs(y=expression(paste('St0' [2], ' (simulated)')))+
1611     scale_x_continuous(breaks=c(0,2,5,7,10))+
1612     theme_classic()+
1613     theme(
1614       axis.text=element_text(size=22)
1615     )+
1616     thm+
1617     thm1
1618
1619
1620
1621 #posthoc comparisons for the linear model
1622 #library(multcomp)
1623
1624
1625 #summary(glht(lm1, linfct = mcp(Group = 'Tukey'))))
1626 #summary(glht(lm1, linfct=mcp(Group="Tukey", interaction_average=TRUE)))
1627

```

## C.2 Working with Missing data in GAMs

This code chunk first randomly deletes 40% of the total observations in the original simulated data, and then an interaction GAM is fitted to the remaining data. Model diagnostics are presented, and an object that stores the fitted smooths is saved to be called in the final code chunk to build the figure.

```
#missing data
#create a sequence of 40 random numbers between 1 and 100, these numbers
  will
#correspond to the row numbers to be randomly erased from the original
  dataset

missing <- sample(1:100, 40)

#create a new dataframe from the simulated data with 40 rows randomly
  removed, keep the missing values as NA

ind <- which(dat_sim$StO2_sim %in% sample(dat_sim$StO2_sim, 40))

#create a new dataframe, remove the StO2 column
dat_missing <- dat_sim[,-1]

#add NAs at the ind positions
dat_missing$StO2_sim[ind]<-NA

#Count the number of remaining observations per day (original dataset had
  10 per group per day)
dat_missing %>%
  group_by(Day,Group) %>%
  filter(!is.na(StO2_sim))%>%
  count(Day)

#the same model used for the full dataset
mod_m1 <- gam(StO2_sim ~ Group+s(Day,by=Group,k=5), data = dat_missing,
  family=scat)
#appraise the model
appraise(mod_m1)

m_predict <- expand_grid(Group = factor(c("Control", "Treatment")),
  Day = seq(0, 10, by = 0.1))

#adds the predictions to the grid and creates a confidence interval
m_predict<-m_predict%>%
  mutate(fit = predict(mod_m1,m_predict,se.fit = TRUE,type='response')$
    fit,
    se.fit = predict(mod_m1, m_predict,se.fit = TRUE,type='response'
    )$se.fit)

f6<-ggplot(data=dat_missing, aes(x=Day, y=StO2_sim, group=Group)) +
  geom_point(aes(color=Group),size=1.5,alpha=0.5,show.legend = FALSE)+
  geom_ribbon(aes( x=Day,ymin=(fit - 2*se.fit),
    ymax=(fit + 2*se.fit),
```

```

1682         fill=Group
1683     ),
1684     alpha=0.3,
1685     data=m_predict,
1686     show.legend=FALSE,
1687     inherit.aes=FALSE) +
1688     geom_line(aes(y=fit,
1689                 color=Group),
1690             size=1, data=m_predict,
1691             show.legend = TRUE)+
1692     #facet_wrap(~Group)+
1693     labs(y=expression(atop(StO2[2], 'missing')))+
1694     scale_x_continuous(breaks=c(0,2,5,7,10))+
1695     theme_classic()+
1696     theme(
1697         axis.text=element_text(size=22)
1698     )+
1699     thm+
1700     thm1
1701

```




Figure 12: Simulated data and smooths for oxygen saturation in tumors. A: Simulated data that follows previously reported trends (inset) in tumors under chemotherapy (Treatment) or saline (Control) treatment. Simulated data is from a normal distribution with standard deviation of 10% with 10 observations per time point. Lines indicate mean oxygen saturation B: Smooths from the GAM model for the full simulated data with interaction of Group and Treatment. Lines represent trends for each group, shaded regions are 95% confidence intervals. C: rm-ANOVA model for the simulated data, the model does not capture the changes in each group over time. D: Smooths for the GAM model for the simulated data with 40% of its observations missing. Lines represent trends for each group, shaded regions are 95% confidence intervals.

### C.3 Pairwise comparisons in GAMs: full and missing data cases

The next code chunk reproduces Figure 4. Here pairwise comparisons are made for the full and missing datasets.

```
##Pairwise comparisons

pdat <- expand.grid(Day = seq(0, 10, length = 400),
                  Group = c('Control', 'Treatment'))

#this function takes the model, grid and groups to be compared using the
  lpmatrix
#originally developed by G. Simpson:
#https://fromthebottomoftheheap.net/2017/10/10/difference-splines-i/

smooth_diff <- function(model, newdata, g1, g2, alpha = 0.05,
                        unconditional = FALSE) {
  xp <- predict(model, newdata = newdata, type = 'lpmatrix')
  #Find columns in xp where the name contains "Control" and "Treatment"
  col1 <- grepl(g1, colnames(xp))
  col2 <- grepl(g2, colnames(xp))
  #Find rows in xp that correspond to each treatment
  row1 <- with(newdata, Group == g1)
  row2 <- with(newdata, Group == g2)
  ## difference rows of xp for data from comparison
  X <- xp[row1, ] - xp[row2, ]
  ## zero out cols of X related to splines for other lochs
  X[, ! (col1 | col2)] <- 0

  ## zero out the parametric cols
  #This line has been commented to keep the comparison at the response
    level,
  #otherwise it gives the marginal change between smooths
  #X[, !grepl('^s\\(', colnames(xp))] <- 0
  dif <- X %*% coef(model)
  #get standard error, critical value and boundaries
  se <- sqrt(rowSums((X %*% vcov(model, unconditional = unconditional))
    * X))
  crit <- qt(alpha/2, df.residual(model), lower.tail = FALSE)
  upr <- dif + (crit * se)
  lwr <- dif - (crit * se)
  data.frame(pair = paste(g1, g2, sep = '-'),
            diff = dif,
            se = se,
            upper = upr,
            lower = lwr)
}

#use the function to calculate the difference in smooths
comp1<-smooth_diff(m1,pdat,'Control','Treatment')

#Create a dataframe with time, comparisons and labels for regions where
  difference exists
comp_St02_full <- cbind(Day = seq(0, 10, length = 400),
                      rbind(comp1)) %>%
```



```

1756 mutate(interval=case_when(
1757     upper>0 & lower<0~"no-diff",
1758     upper<0~"less",
1759     lower>0~"greater"
1760 ))
1761
1762 pairwise_limits<-function(dataframe){
1763     #extract values where the lower limit of the ribbon is greater than
1764     zero
1765     #this is the region where the control group effect is greater
1766     v1<-dataframe%>%
1767         filter(lower>0)%>%
1768         select(Day)
1769     #get day initial value
1770     init1=v1$Day[[1]]
1771     #get day final value
1772     final1=v1$Day[[nrow(v1)]]
1773
1774     #extract values where the value of the upper limit of the ribbon is
1775     lower than zero
1776     #this corresponds to the region where the treatment group effect is
1777     greater
1778     v2<-comp_StO2_full%>%
1779         filter(upper<0)%>%
1780         select(Day)
1781
1782     init2=v2$Day[[1]]
1783     final2=v2$Day[[nrow(v2)]]
1784     #store values
1785     my_list<-list(init1=init1,
1786                   final1=final1,
1787                   init2=init2,
1788                   final2=final2)
1789     return(my_list)
1790 }
1791
1792 my_list<-pairwise_limits(comp_StO2_full)
1793
1794 c1<-ggplot(comp_StO2_full, aes(x = Day, y = diff, group = pair)) +
1795     annotate("rect",
1796             xmin =my_list$init1, xmax =my_list$final1,ymin=-Inf,ymax=
1797             Inf,
1798             fill='#30123BFF',
1799             alpha = 0.5,
1800             ) +
1801     annotate("text",
1802             x=1.5,
1803             y=-18,
1804             label="Control>Treatment",
1805             size=8,
1806             angle=90
1807             )+
1808     annotate("rect",
1809             xmin =my_list$init2, xmax =my_list$final2,ymin=-Inf,ymax=Inf,

```

```

1810         fill='#7A0403FF',
1811         alpha = 0.5,
1812     ) +
1813     annotate("text",
1814             x=6,
1815             y=-18,
1816             label="Treatment>Control",
1817             size=8,
1818             angle=90
1819         )+
1820     geom_ribbon(aes(ymin = lower, ymax = upper),
1821               alpha = 0.5,
1822               fill='#DB3A07FF') +
1823     geom_line(data=comp_St02_full,aes(y=0),size=0.5)+
1824     geom_line(color='black',size=1) +
1825
1826     facet_wrap(~ pair) +
1827     theme_classic()+
1828     labs(x = 'Days', y = expression(paste('Difference in St0'[2] )))+
1829     scale_x_continuous(breaks=c(0,2,5,7,10))+
1830     theme(
1831         text=element_text(size=18),
1832         legend.title=element_blank()
1833     )
1834
1835
1836 ###for missing data
1837 comp2<-smooth_diff(mod_m1,pdat,'Control','Treatment')
1838 comp_St02_missing <- cbind(Day = seq(0, 10, length = 400),
1839                            rbind(comp2))
1840
1841 missing_plot<-ggplot(comp_St02_missing, aes(x = Day, y = diff, group =
1842 pair)) +
1843     geom_ribbon(aes(ymin = lower, ymax = upper), alpha = 0.2) +
1844     geom_line(color='black',size=1) +
1845     facet_wrap(~ pair) +
1846     labs(x = 'Days',
1847          y = expression(paste('Difference in St0'[2],'\n (missing data)'
1848                               )))
1849     scale_x_continuous(breaks=c(0,2,5,7,10))+
1850     theme_classic()+
1851     theme(
1852         text=element_text(size=18),
1853         legend.title=element_blank()
1854     )
1855
1856 my_list<-pairwise_limits(comp_St02_missing)
1857
1858 c2<-ggplot(comp_St02_missing, aes(x = Day, y = diff, group = pair)) +
1859     annotate("rect",
1860             xmin =my_list$init1, xmax =my_list$final1,ymin=-Inf,ymax=Inf,
1861             fill='#30123BFF',
1862             alpha = 0.5,
1863         ) +

```

```

1864   annotate("text",
1865           x=1.5,
1866           y=-18,
1867           label="Control>Treatment",
1868           size=8
1869         )+
1870   annotate("rect",
1871           xmin =my_list$init2, xmax =my_list$final2,ymin=-Inf,ymax=Inf,
1872           fill='#7A0403FF',
1873           alpha = 0.5,
1874         ) +
1875   annotate("text",
1876           x=6,
1877           y=-18,
1878           label="Treatment>Control",
1879           size=8)+
1880   geom_ribbon(aes(ymin = lower, ymax = upper),
1881             alpha = 0.5,
1882             fill='#DB3A07FF') +
1883   geom_line(data=comp_St02_missing,aes(y=0),size=0.5)+
1884   geom_line(color='black',size=1) +
1885   facet_wrap(~ pair) +
1886   theme_classic()+
1887   labs(x = 'Days', y = expression(paste('Difference in St0'[2] )))+
1888   scale_x_continuous(breaks=c(0,2,5,7,10))+
1889   theme(
1890     text=element_text(size=18),
1891     legend.title=element_blank()
1892   )
1893
1894 pair_comp<-c1+c2
1895

```




Figure 13: Pairwise comparisons for smooth terms. A: Pairwise comparisons for the full dataset. B: Pairwise comparisons for the dataset with missing observations. Significant differences exist where the interval does not cover 0. In both cases the effect of treatment is significant after day 3.